HOME
>
臨床医学：内科
>
呼吸器一般
> 最新　呼吸器内科・外科学

最新　呼吸器内科・外科学

出版社：	メディカルレビュー社
著者：	伊達洋至平井豊博(監修)
発行日：	2019-10-30
分野：	臨床医学：内科 > 呼吸器一般
ISBN：	9784779223150
電子書籍版：	2019-10-30 （第1版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

22,000 円(税込)

購入する

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

商品紹介

呼吸器の疫学、呼吸器系の解剖と機能、主要症候と身体所見、胸部画像診断、検査・介入手技から、各疾患の診断・治療までを網羅し、わかりやすく解説する。電子版を閲覧できるIDとパスワード付き。

目次

総論
　1．呼吸器の疫学
　2．呼吸器系の解剖と機能
　3．主要症候と身体所見
　4．胸部画像診断
　5．検査・介入手技
　6．呼吸器疾患の治療

各論
　1．主な疾患
　2．胸膜、縦隔、横隔膜、胸郭の疾患
　3．胸部外傷および胸部救急

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

総論

P.6 掲載の参考文献

1) 厚生労働省. 平成28年人口動態統計月報年計 (概数) の概況. 2017. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai16/dl/gaikyou28.pdf

2) 川名明彦, 他. 呼吸器感染症 2015. 日本胸部臨床 (増刊). 2015.

3) 一般社団法人GOLD日本委員会. COPD情報サイト. 2017. http://www.gold-jac.jp/

4) 井上博雅, 他. 気管支喘息. 呼吸器疾患診断治療アプローチ. 東京 : 中山書店 ; 2017.

5) 難病情報センター. 難病対策の概要. 2017. http://www.nanbyou.or.jp/entry/1360

P.14 掲載の参考文献

1) Sobotich D. Variations of pulmonary vessels : some practical implications for lung resections. Clin Anat. 2009 ; 22 : 698-705.

2) Yamashita H. Roentgenologic anatomy of the lung. Tokyo : Igaku-syoin ; 1978.

3) Cauldwell EW, et al. The bronchial arteries : an anatomic study of 105 human cadavers. Surg Gynecol Obstet. 1948 ; 86 : 395-412.

4) Sugi K, et al. Effect of radioisotope sentinel node mapping in patients with cT1 N0 M0 lung cancer. J Thorac Cardiovasc Surg. 2003 ; 126 (2) : 568-73.

5) Nomori H. Sentinel node mapping in lung cancer : the Japanese experience. Semin Thorac Cardiovasc Surg. 2009 ; 21 (4) : 316-22.

6) Sonobe M, et al. Prognostic factors after complete resection of pN2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013 ; 146 (4) : 788-95.

7) Giles CL, et al. Horner's syndrome : an analysis of 216 cases. Am J Ophthalmol. 1958 ; 46 (3 Pt 1) : 289-96.

8) Riley EA. Idiopathic diaphragmatic paralysis ; a report of eight cases. Am J Med. 1962 ; 32 : 404-16.

P.18 掲載の参考文献

1) Volckaert T, et al. Wnt and FGF mediated epithelial-mesenchymal crosstalk during lung development. Dev Dyn. 2015 ; 244 (3) : 342-66.

2) Rackley CR, et al. Building and maintaining the epithelium of the lung. J Clin Invest. 2012 ; 122 (8) : 2724-30.

3) Nikolic MZ, et al. Human embryonic lung epithelial tips are multipotent progenitors that can be expanded in vitro as long-term self-renewing organoids. Elife. 2017 ; 6. pii : e26575. doi : 10.7554/eLife.26575.

4) Chida S, et al. Stable microbubble test for predicting the risk of respiratory distress syndrome : I. Comparisons with other predictors of fetal lung maturity in amniotic fluid. Eur J Pediatr. 1993 ; 152 (2) : 148-51.

5) Wijnberger LD, et al. Prediction of fetal lung immaturity using gestational age, patient characteristics and fetal lung maturity tests : a probabilistic approach. Arch Gynecol Obstet. 2010 ; 281 (1) : 15-21.

6) Narayanan M, et al. Alveolarization continues during childhood and adolescence : new evidence from helium-3 magnetic resonance. Am J Respir Crit Care Med. 2012 ; 185 (2) : 186-91.

P.21 掲載の参考文献

1) Bals R, et al. Innate immunity in the lung : how epithelial cells fight against respiratory pathogens. Eur Respir J. 2004 ; 23 : 327-33.

2) Byrne AJ, et al. Pulmonary macrophages : key players in the innate defence of the airways. Thorax. 2015 ; 70 : 1189-96.

3) 佐藤篤彦. BALT (bronchus-associated lymphoid tissue) の基礎的, 臨床的展望. 日呼吸会誌. 2000 ; 38 (1). 3-11.

P.23 掲載の参考文献

1) West JB, et al. ウエスト呼吸生理学入門正常肺編第2版. 10th ed. 桑平一郎 (訳). 東京 : メディカル・サイエンス・インターナショナル ; 2017.

P.25 掲載の参考文献

1) Janssens JP, et al. Physiological changes in respiratory function associated with ageing. Eur Respir J. 1999 ; 13 : 197-205.

2) Verbeken EK, et al. The senile lung. Comparison with normal and emphysematous lungs. 1. Structural aspects. Chest. 1992 ; 101 : 793-9.

3) Polkey MI, et al. The contractile properties of the elderly human diaphragm. Am J Respir Crit Care Med. 1997 ; 155 : 1560-4.

4) Svartengren M, et al. Long-term clearance from small airways decreases with age. Eur Respir J. 2005 ; 26 : 609-15.

P.34 掲載の参考文献

1) American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995 ; 152 : 1107-36.

2) Miller MR, et al. Standardisation of spirometry. Eur Respir J. 2005 ; 26 : 319-38.

3) 日本呼吸器学会. 呼吸機能検査ガイドライン-スパイロメトリー, フローボリューム曲線, 肺拡散能力-. 日本呼吸器学会肺生理専門委員会 (編). 東京 : メディカルレビュー社 ; 2004.

4) 日本呼吸器学会肺生理専門委員会 : 日本人のスパイログラムと動脈血液ガス分圧基準値. 日呼会誌. 2001 ; 39 : 1-17.

5) Kubota M, et al ; Clinical Pulmonary Functions Committee of the Japanese Respiratory Society. (2014). Reference values for spirometry, including vital capacity, in Japanese adults calculated with the LMS method and compared with previous values. Respir Investig. 2014 ; 52 (4) : 242-50. doi : 10.1016/j.resinv.2014.03.003.

6) Tanimura K, et al. Comparison of two devices for respiratory impedance measurement using a forced oscillation technique : basic study using phantom models. J Physiol Sci. 2014 ; 64 (5) : 377-82. doi. 10.1007/s12576-014-0329-4

P.39 掲載の参考文献

1) Wagner PD, et al. Ventilation-perfusion inequality in chronic obstructive pulmonary disease. J Clin Invest. 1977 ; 59 (2) : 203-16. http://doi.org/10.1172/JCI108630

2) Wagner PD, et al. Continuous distributions of ventilation-perfusion ratios in normal subjects breathing air and 100 per cent O2. J Clin Invest. 1974 : 54 (1), 54-68. http://doi.org/10.1172/JCI107750

3) 日本呼吸器学会肺生理専門委員会 (編). 呼吸機能検査ガイドライン-スパイロメトリー, フローボリューム曲線, 肺拡散能力-. 東京 : メディカルレビュー社 ; 2004

4) 日本呼吸器学会COPDガイドライン第5版作成委員会 (編). COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第5版. 東京 : メディカルレビュー社 ; 2018.

5) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会 (編). 特発性間質性肺炎診断と治療の手引き (改訂第3版). 東京 : 南江堂 ; 2016.

6) 日本呼吸器外科学会. 肺癌手術の呼吸機能からのリスク評価の指針. https://www.jacsurg.gr.jp/committee/riskappraisal.pdf

P.43 掲載の参考文献

1) 松本久子. 喘息診療における呼気中NO肺胞成分 (alveolar NO) 測定の意義 "専門医のためのアレルギー学講座". 日本アレルギー学会誌. 2012 ; 61 : 760-9.

2) Matsunaga K, et al. Exhaled nitric oxide cutoff values for asthma diagnosis according to rhinitis and smoking status in Japanese subjects. Allergol Int. 2011 ; 60 : 331-7.

3) 日本呼吸器学会. 呼気一酸化窒素 (NO) 測定ハンドブック作成委員会, 日本呼吸器学会肺生理専門委員会 (編). 呼気一酸化窒素 (NO) 測定ハンドブック. 東京 : メディカルレビュー社 ; 2018.

4) Dweik RA, et al. An official ATS clinical practice guideline : interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011 ; 184 : 602-15.

5) Sato S, et al. Optimal cutoff level of breath carbon monoxide for assessing smoking status in patients with asthma and COPD. Chest. 2003 ; 124 (5) : 1749-54.

6) Kharitonov SA, et al. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med. 2001 ; 163 (7) : 1693-722. doi : 10.1164/ajrccm.163.7.2009041.

7) Zayasu K, et al. Increased carbon monoxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med. 1997 ; 156 (4 Pt 1) : 1140-3. doi : 10.1164/ajrccm.156.4.96-08056.

8) Bhavani-Shankar K, et al. Terminology and the current limitations of time capnography : a brief review. J Clin Monit. 1995 ; 11 (3) : 175-82.

P.47 掲載の参考文献

1) Berger AJ, et al. Regulation of respiration. N Engl J Med. 1977 ; 297 : 92-7, 138-43, 194-201.

2) 日本呼吸器学会肺生理専門委員会. 基本編 5. Chest wallと呼吸筋, 基本編 13. 呼吸調節. 臨床呼吸機能検査第8版, 東京 : メディカルレビュー社 ; 2016. 46-58, 128-35.

3) Agostoni E, et al. Statics of the chest wall. In : Roussos C, et al. eds. The Thorax. vol. 29A. New York : Marce Dekker ; 1985. pp. 259-95.

P.51 掲載の参考文献

1) 日本呼吸器学会肺生理専門委員会 (編). 基本編 10. 血液ガス, 基本編 11. パルスオキシメータと臨床応用, 基本編 12. 酸塩基調節. 臨床呼吸機能検査第8版. 東京 : メディカルレビュー社 ; 2016.

2) 日本呼吸ケア・リハビリテーション学会酸素療法マニュアル作成委員会, 日本呼吸器学会肺生理専門委員会 (編). 酸素療法マニュアル (酸素療法ガイドライン改定版). 東京 ; メディカルレビュー社 ; 2017.

P.56 掲載の参考文献

1) 日本アレルギー学会喘息ガイドライン専門部会 (監). 喘息予防・管理ガイドライン 2018. 東京 : 協和企画 ; 2018.

2) 新実彰男, 他. 咳感受性試験. 呼と循. 2008 ; 56 : 1153-7.

3) Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, Update 2018. https://ginasthma.org/gina-reports/. (Last accessed : Jan. 2019)

4) Global Initiative for Chronic Obstructive Lung Disease (GOLD). GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. https://goldcopd.org/gold-reports/. (Last accessed : Jan. 2019)

5) Marotta A, et al. Impulse oscillometry provides an effective measure of lung dysfunction in 4-year-old children at risk for persistent asthma. J Allergy Clin Immunol. 2003 Aug ; 112 (2) : 317-22.

6) Albert P, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012 ; 67 : 701-8.

7) Cockcroft DW, et al. Direct and indirect challenges in the clinical assessment of asthma. Ann Allergy Asthma Immunol. 2009 ; 103 : 363-70.

8) 新実彰男. 気道過敏性検査. 日胸 71 (増刊号). 2012 : S27-33.

9) Takishima T, et al. Direct-writing recorder of the dose-response curves of the airway to methacholine. Chest. 1981 ; 80 : 600-6.

10) Niimi A, et al. Relationship of airway wall thickness to airway sensitivity and airway reactivity in asthma. Am J Respir Crit Care Med. 2003 ; 168 : 983-8.

P.59 掲載の参考文献

1) 日本呼吸ケア・リハビリテーション学会, 他 (編). 呼吸リハビリテーションマニュアル-運動療法-第2版. 東京 : 照林社 ; 2012.

2) 日本呼吸器学会 (編). COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第4版. 東京 : メディカルレビュー社 ; 2013.

3) Puente-Maestu L, et al. Use of exercise testing in the evaluation of interventional efficacy : an official ERS statement. Eur Respir J. 2016 ; 47 : 429-60.

P.62 掲載の参考文献

1) 陳和夫. 呼吸調節機能検査. 金澤一郎, 他 (編). 内科学 1. 東京 : 医学書院 ; 2006. p.1015-6.

2) Burki NK. Measurement of ventilatory regulation. Clin Chest Med. 1999 ; 10 : 215-26.

3) Simon PW, et al. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis. 1990 ; 142 : 1009-14.

4) Mahler DA, et al. Dyspnea. In : Fishman AP, editor. Pulmonary Rehabilitation. Lung Biology in Health and Disease, vol 91. New York : Marcel Dekker ; 1996. p.97-116.

P.66 掲載の参考文献

1) American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Orlando : American Academy of Sleep Medicine ; 2014.

2) 上田和幸, 他. 簡易モニターと終夜睡眠ポリソムノグラフィ, 経皮PCO2モニター, 反復睡眠潜時検査. Medicina. 2011 ; 48 : 970-4.

3) 日本呼吸器学会肺生理専門委員会 (編). 応用編 11. 睡眠呼吸障害. 臨床呼吸機能検査第8版. 東京 : メディカルレビュー社 ; 2016.

P.69 掲載の参考文献

1) Crombie DL. Diagnostic process. J Coll Gen Pract. 1963 ; 6 : 579-89.

2) Hampton JR, et al. Relative contributions of history-taking, physical examination, and laboratory investigation to diagnosis and management of medical outpatients. Br Med J. 1975 ; 2 : 486-9.

3) Sandler G. The importance of the history in the medical clinic and the cost of unnecessary tests. Am Heart J. 1980 ; 100 : 928-31.

4) Peterson MC, et al. Contributions of the history, physical examination, and laboratory investigation in making medical diagnoses. West J med. 1992 ; 156 : 163-5.

5) 宮下淳. 病院総合医の臨床能力を鍛える本. 東京 : カイ書林 ; 2012. pp. 35-6.

P.76 掲載の参考文献

1) 日本呼吸器学会咳嗽・喀痰の診療ガイドライン2019作成委員会 (編). 咳嗽・喀痰の診療ガイドライン 2019. 東京 : メディカルレビュー社 ; 2019.

2) Matsumoto H, et al. Risks and cough-aggravating factors in prolonged cough : epidemiological observations from the Nagahama Cohort Study. Ann Am Thorac Soc. 2017 ; 14 : 698-705.

3) Niimi A, et al. Eosinophilic airway disorders associated with chronic cough. Pulm Pharmacol Ther. 2009 ; 22 : 114.

4) Fujimura M, et al. Comparison of atopic cough with cough variant asthma : Is atopic cough a precursor of asthma? Thorax. 2003 ; 58 : 14-8.

5) Kahrilas PJ, et al. Chronic cough due to gastroesophageal reflux in adults. CHEST guideline and expert panel report. Chest. 2016 ; 150 : 1341-60.

6) Irwin RS. Evaluation of wheezing illnesses other than asthma in adults. UpToDate 2017.

P.80 掲載の参考文献

1) Miller DL, et al. THE BACTERIAL FLORA OF THE UPPER RESPIRATORY TRACT AND SPUTUM OF WORKING MEN. J Pathol Bacteriol. 1964 ; 87 : 182-6.

2) Geckler RW, et al. Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates. J Clin Microbiol. 1977 ; 6 (4) : 396-9.

3) 日本呼吸器学会COPDガイドライン第5版作成委員会 (編). COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第5版. 東京 : メディカルレビュー社 ; 2018.

4) Tagaya E, et al. Effect of tiotropium on mucus hypersecretion and airway clearance in patients with COPD. Pulm Pharmacol Ther. Jun 2016 ; 1-4. doi : 10.1016/j.pupt.2016.06.008.

P.83 掲載の参考文献

1) Earwood JS, et al. Hemoptysis : Evaluation and Management. Am Fam Physician. 2015 ; 91 : 243-9.

2) 米丸亮. 喀血への保存的対応と基礎疾患の治療. 日胸. 2006 ; 65 : 687-97.

3) 木村哲也. 血痰・喀血. 救急医学. 2013 ; 37 : 634-8.

4) 高橋典明. 喀血に対する気管支ファイバースコピーについて. 日気食会報. 2014 ; 65 : 180-2.

5) 石川秀雄, 他. 大量喀血の治療戦略. 呼吸. 2014 ; 33 : 252-8.

6) Simpson JR, et al. Palliative radiotherapy for inoperable carcinoma of the lung : final report of a RTOG multi-institutional trial. Int J Radiat Oncol Bio Phys. 1985 ; 11 : 751-8.

P.86 掲載の参考文献

1) 工藤翔二 (編). 呼吸器専門医テキスト第3版. 東京 : 南江堂 ; 2010. p.47-9.

2) 杉山幸比古 (編). 講義録呼吸器学第2版. 東京 : メジカルビュー ; 2006. p.94-7.

3) Wells PS, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism : increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000 ; 83 : 416-20.

4) 金澤一郎, 他. 今日の診断指針第7版. 東京 : 医学書院 ; 2015. p.1043-6.

P.91 掲載の参考文献

1) Dyspnea. Mechanisms, assessment, and management : a consensus statement. American Thoracic Society. Am J Respir Crit Care Med. 1999 ; 159 (1) : 321-40.

2) Mahler DA, et al. Dyspnea : Mechanisms, Measurement, and Management. 3rd ed. Florida : CRC Press ; 2014.

3) 泉崎雅彦, 他. 呼吸困難感のメカニズム. 呼と循. 2003 ; 51 (1) : 57-65.

4) 小川浩正. 呼吸器疾患の呼吸困難の機序. 呼と循. 2003 ; 56 (1) : 25-35.

5) Nishimura K, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002 ; 121 (5) : 1434-40.

6) 日本呼吸器学会COPDガイドライン第5版作成委員会 (編). COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン 2018 [第5版]. 東京 : メディカルレビュー社 ; 2018.

7) 日本緩和医療学会緩和医療ガイドライン作成委員会 (編). がん患者の呼吸器症状の緩和に関するガイドライン (2016年版). 東京 : 金原出版 ; 2016.

P.94 掲載の参考文献

1) Drake RD, 他. グレイ解剖学原著第二版. 東京 : エルゼビア・ジャパン ; 2011. p.966.

2) 大上研二. 内科医が留意すべき耳鼻科疾患の診断と治療, 予防-患者の症状から見逃さないためのコツとポイント-11) 嗄声. Prog Med. 2010 ; 30 : 1087-93.

3) 高北晋一. 嗄声. 臨床研修プラクティス. 2007 ; 4 : 40-1.

4) 赤田壮一, 他. 嗄声. 臨床画像. 2013 ; 10 (増刊号) : 79-86.

5) 平野滋. 音声障害を来す疾患の診断と治療. 日本耳鼻咽喉学会会報. 2014 ; 117 : 834-7.

P.97 掲載の参考文献

1) Willis GC. Dr. ウィリスベッドサイド診断-病歴と身体診察でここまでわかる! 松村理司 (監訳). 東京 : 医学書院 ; 2008. pp.28-9.

2) ハリソン内科学第4版. 福井次矢, 黒川清 (監). 東京 : メディカル・サイエンス・インターナショナル ; 2013. pp.244-5.

3) McGee S. Evidence based physical diagnosis. 2nd ed. Philadelphia : Saunders Elsevier ; 2007. p.303.

4) Myers KA, et al. The rational clinical examination. Does this patient have clubbing? JAMA. 2001 ; 286 (3) : 341-7.

5) Spicknall KE, et al. Clubbing : an update on diagnosis, differential diagnosis, pathophysiology, and clinical relevance. J Am Acad Dermatol. 2005 ; 52 (6) : 1020-8.

P.102 掲載の参考文献

1) 佐藤光夫, 他. 腫瘍随伴症候群-基礎と臨床の最新研究動向-. 日本臨床. 2013 ; 71 : 186-91.

2) Graus F, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004 ; 75 : 1135-40.

3) 田中恵子. 傍腫瘍性神経症候群. 医学のあゆみ. 2015 ; 255 : 543-7.

4) 今泉和良, 他. Lambert-Eaton症候群. 呼吸. 2013 ; 32 : 948-52.

5) Alamowitch S, et al. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain. 1997 ; 120 : 923-8.

P.106 掲載の参考文献

1) 桑平一郎 (訳). ウエスト呼吸生理学入門. West JB. Respiratory Physiology THE ESSENTIALS. 8th ed. 東京 : メディカル・サイエンス・インターナショナル ; 2009.

2) 川上義和 (編). 呼吸調節のしくみベッドサイドへの応用. 東京 : 文光堂 ; 1997.

3) Kryger MH. Introduction to Respiratory Medicine. 2nd ed. New York : Churchill Livingstone ; 1990.

4) Ohi M, et al. Oxygen desaturation following voluntary hyperventilation in normal subjects. Am J Respir Crit Care Med. 1994 ; 149 : 731-8.

P.109 掲載の参考文献

1) 長坂行雄. 胸痛の診察. 呼吸と循環. 2016 ; 64 : 777-83.

2) 工藤翔二. 肺聴診の歴史散歩, 肺聴診の科学. 工藤翔二 (監修). 聴いて見て考える肺の聴診. 東京 : アトムス ; 2014. pp. 1-14.

3) Shimoda T, et al. Lung sound analysis and airway inflammation in bronchial asthma. J Allergy Clin Immunol Pract. 2016 ; 4 : 505-11.

4) Nagasaka Y. Lung sounds in bronchial asthma. Allergol International. 2012 ; 61 : 353-63.

5) 長坂行雄. 断続性雑音と胸膜摩擦音. 呼吸器ジャーナル. 2017 ; 65 : 354-9.

P.111 掲載の参考文献

1) 長坂行雄. 呼吸器疾患の診断-初めはバイタルサインから. 呼吸と循環. 2016 ; 64 : 372-6.

2) 長坂行雄. チアノーゼとばち指. 楽しく学ぶ身体所見-呼吸器診療へのアプローチ. 東京 : 克誠堂 ; 2011. pp.23-5.

3) 長坂行雄. 喉の違和感と痛み. 呼吸と循環. 2016 ; 64 : 1102-7.

4) 長坂行雄. 発汗. 楽しく学ぶ身体所見-呼吸器診療へのアプローチ. 東京 : 克誠堂 ; 2011. pp.29-30.

P.116 掲載の参考文献

1) 久保武. わかりやすい胸部画像診断胸部X線をどう見るか. 日呼吸ケアリハ会誌. 2015 ; 25 (2) : 180-5.

2) 原眞咲, 他. 画像診断の基礎胸部X線画像. 日独医報. 2014 ; 59 (1) : 6-28.

3) 大石展也. 心不全評価のための検査胸部X線所見の読み方とコツ. 診断と治療. 2015 ; 103 (Suppl) : 56-61.

4) Rankin JA. van Leeuwenhoek's disease. Am J Respir Crit Care Med. 2011 ; 183 (10) : 1434.

P.120 掲載の参考文献

1) Dalrymple NC, et al. Informatics in radiology (infoRAD) : introduction to the language of three-dimensional imaging with multidetector CT. Radiographics. 2005 Sep-Oct ; 25 (5) : 1409-28.

2) Willemink MJ, et al. Iterative reconstruction techniques for computed tomography Part 1 : Technical principles. Eur Radiol. 2013 Jun ; 23 (6) : 1623-31.

3) Kubo T, et al. Securing safe and informative thoracic CT examinations-Progress of radiation dose reduction techniques. Eur J Radiol. 2017 Jan ; 86 : 313-9.

4) Sullivan DC, et al. Metrology Standards for Quantitative Imaging Biomarkers. Radiology. 2015 Dec ; 277 (3) : 813-25.

P.123 掲載の参考文献

1) Inaoka T, et al. Thymic hyperplasia and thymus gland tumors : differentiation with chemical shift MR imaging. Radiology. 2007 ; 243 (3) : 869-76.

2) Priola AM, et al. Differentiation of rebound and lymphoid thymic hyperplasia from anterior mediastinal tumors with dual-echo chemical-shift MR imaging in adulthood : reliability of the chemical-shift ratio and signal intensity index. Radiology. 2015 ; 274 (1) : 238-49.

3) Ohno Y, et al. Pulmonary high-resolution ultrashort TE MR imaging : Comparison with thin-section standardand low-dose computed tomography for the assessment of pulmonary parenchyma diseases. J Magn Reson Imaging. 2016 ; 43 (2) : 512-32.

4) 那須克宏. 肺癌および縦隔腫瘍の診断におけるMRIの役割. 肺癌. 2012 ; 52 (3) : 326-35.

P.128 掲載の参考文献

1) Beigelman-Aubry C, et al. Management of an incidentally discovered pulmonary nodule. Eur Radiol. 2007 Feb ; 17 (2) : 449-66.

2) Wang CW, et al. Intrapulmonary lymph nodes : computed tomography findings with histopathologic correlations. Clin. Imaging. 2013 May-Jun ; 37 (3) : 487-92.

3) Naidich DP, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT : a statement from the Fleischner Society. Radiology. 2013 Jan ; 266 (1) : 304-17.

4) 高橋雅士, 他. 所見から迫る胸部CT 小葉 (細葉) 中心性分布. 日胸臨. 2015 ; 74 (9) : 977-87.

P.132 掲載の参考文献

1) 日本胸腺研究会. 縦隔区分の方法と占拠部位の記載. 臨床・病理 : 縦隔腫瘍取り扱い規約. 東京 : 金原出版 ; 2009. pp. 2-8.

2) Fujimoto K, et al. Proposal for a new mediastinal compartment classification of transverse plane images according to the Japanese Association for Research on the Thymus (JART) General Rules for the Study of Mediastinal Tumors. Oncol Rep. 2014 Feb ; 31 (2) : 565-72.

3) Carter BW, et al. A modern definition of mediastinal compartments. J Thorac Oncol. 2014 Sep ; 9 (9 Suppl 2) : S97-101.

4) Vargas D, et al. Cystic Lesions of the Mediastinum. Semin Ultrasound CT MR. 2016 Jun ; 37 (3) : 212-22.

5) Carter BW, et al. Approaching the patient with an anterior mediastinal mass : a guide for radiologists. J Thorac Oncol. 2014 Sep ; 9 (9 Suppl 2) : S110-8.

P.135 掲載の参考文献

1) Arenas-Jimenez J, et al. Evaluation of CT findings for diagnosis of pleural effusions. Eur Radiol. 2000 ; 10 (4) : 681-90.

2) Abramowitz Y, et al. Pleural effusion : characterization with CT attenuation values and CT appearance. AJR Am J Roentgenol. 2009 Mar ; 192 (3) : 618-23.

3) 加藤勝也. 所見から迫る胸部CT 胸膜肥厚. 日胸臨. 2016 ; 75 (4) : 407-16.

4) 稲福賢司, 他. 術前に肺癌と診断された限局性悪性胸膜中皮腫の1切除例. 肺癌. 2016 ; 56 (7) : 1040-5.

5) 林賢, 他. 原発性悪性胸壁腫瘍の臨床病理学的検討. 日胸外会誌. 1990 ; 38 (7) : 1099-105.

P.139 掲載の参考文献

1) Haldar S, et al. Most patients with isolated subsegmental pulmonary embolism do not need anticoagulants. BMJ. 2013 Aug 20 ; 347 : f5127.

2) Klok FA, et al. Management of incidental pulmonary embolism. Eur Respir J. 2017 Jun 29 ; 49 (6).

3) Fuchigami S, et al. Pulmonary Tumor Thrombotic Microangiopathy-Antemortem Diagnosis With Pulmonary Artery Wedge Blood Cell Sampling in a Recurrent Breast Cancer Patient. Circ J. 2017 Nov 24 ; 81 (12) : 1959-60.

4) Devaraj A, et al. Computed tomography signs of pulmonary hypertension : old and new observations. Clin Radiol. 2009 Aug ; 64 (8) : 751-60.

5) Sanchez Nistal MA. Pulmonary hypertension : the contribution of MDCT to the diagnosis of its different types. Radiologia. 2010 Nov-Dec ; 52 (6) : 500-12.

P.142 掲載の参考文献

1) Khalil A, et al. Utility of high-resolution chest CT scan in the emergency management of haemoptysis in the intensive care unit : severity, localization and aetiology. Br J Radiol. 2007 ; 80 (949) : 21-5.

2) 布浦誓子, 他. 喀血・肺癌に対する血管内治療術前のmultidetector-row CTによる目的血管検索の有用性. 臨床放射線. 2006 ; 51 (1) : 71-7.

3) Yoon W, et al. Massive hemoptysis : prediction of nonbronchial systemic arterial supply with chest CT. Radiology. 2003 ; 227 (1) : 232-8.

4) Sopko DR, et al. Bronchial artery embolization for hemoptysis. Semin Intervent Radiol. 2011 ; 28 (1) : 48-62.

5) Khalil A, et al. Severe hemoptysis of pulmonary arterial origin : Signs and role of multidetector row ct angiography. Chest. 2008 ; 133 (1) : 212-9.

6) Hayakawa K, et al. Bronchial artery embolization for hemoptysis : immediate and long-term results. Cardiovasc Intervent Radiol. 1992 ; 15 (3) : 154-8 ; discussion 8-9.

P.144 掲載の参考文献

1) Faughnan ME, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011 ; 48 (2) : 73-87.

2) Osuga K, et al. Initial experience with use of hydrogel microcoils in embolization of pulmonary arteriovenous malformations. SpringerPlus. 2014 ; 3 : 609.

3) Mager JJ, et al. Embolotherapy of pulmonary arteriovenous malformations : long-term results in 112 patients. J Vasc Interv Radiol. 2004 ; 15 (5) : 451-6.

4) Pollak JS, et al. Clinical and anatomic outcomes after embolotherapy of pulmonary arteriovenous malformations. J Vasc Interv Radiol : JVIR. 2006 ; 17 (1) : 35-44 ; quiz 5.

5) Milic A, et al. Reperfusion of pulmonary arteriovenous malformations after embolotherapy. J Vasc Interv Radiol. 2005 ; 16 (12) : 1675-83.

P.150 掲載の参考文献

1) 小須田茂, 他. 科学的根拠に基づく呼吸器核医学診断 (診療) ガイドライン第2版. 一般社団法人日本核医学会分科会呼吸器核医学研究会呼吸器核医学診断ガイドライン作成委員会 (編). 2015.

2) Bajc M, et al. Perfusion SPECT in patients with suspected pulmonary embolism. Eur J Nucl Med Mol Imaging. 2013 ; 40 : 1432-7.

3) Vidal Melo MF, et al. Spatial heterogeneity of lung perfusion assessed with (13) N PET as a vascular biomarker in chronic obstructive pulmonary disease. J Nucl Med. 2010 ; 51 : 57-65.

P.155 掲載の参考文献

1) Murphy KJ, et al. Etidronate therapy decreases the sensitivity of bone scanning with methylene diphosphonate labelled with technetium-99m. Can Assoc Radiol J. 1997 ; 48 : 199-202.

2) Shi X, et al. Diffuse hepatic and splenic uptake of Tc-99m methylene diphosphonate on bone scintigraphy after intravenous administration of gadolinium-containing MRI contrast. Clin Nucl Med. 2011 ; 36 : 178-82.

3) Liu T, et al. Fluorine-18 deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer : which one is the best?--a meta-analysis. Clin Oncol (R Coll Radiol). 2011 ; 23 : 350-8.

4) Hattner RS, et al. Gallium-67/stable gadolinium antagonism : MRI contrast agent markedly alters the normal biodistribution of gallium-67. J Nucl Med. 1990 ; 31 : 1844-6.

5) Nobashi T, et al. The utility of PET/CT with (68) Ga-DOTATOC in sarcoidosis : comparison with (67) Ga-scintigraphy. Ann Nucl Med. 2016 ; 30 : 544-52.

P.158 掲載の参考文献

1) 日本肺癌学会 (編). EBMの手法による肺癌診療ガイドライン 2017年版. 東京 : 金原出版 ; 2017.

P.161 掲載の参考文献

1) 日本呼吸器学会COPDガイドライン第4版作成委員会 (編). COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第4版. 東京 : メディカルレビュー社 ; 2013.

2) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会 (編). 特発性間質性肺炎診断と治療の手引き改訂第3版. 東京 : 南江堂 ; 2016.

3) 3学会合同ARDS診療ガイドライン2016作成委員会. ARDS診療ガイドライン 2016. 東京 : 一般社団法人日本呼吸器学会 ; 2016.

4) 井上博雅 (専門編集). 呼吸器疾患診断治療アプローチ 1. 気管支喘息. 東京 : 中山書店 ; 2017. pp.150-4.

5) 一般社団法人日本アレルギー学会喘息ガイドライン専門部会「喘息予防・管理ガイドライン 2015」作成委員会 (編). 喘息予防・管理ガイドライン 2015. 東京 : 協和企画 ; 2015.

P.164 掲載の参考文献

1) 三森経世. 膠原病の入り口-診断のこつ. 血液所見. 診断と治療. 2010 ; 98 : 1587-93.

2) Ishikawa N, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012 ; 50 : 3-13.

3) Fischer A, et al. An official European Respiratory Society/American Thoracic Society research statement : interstitial pneumonia with autoimmune features. Eur Respir J. 2015 ; 46 : 976-87.

4) Ishizuka M, et al. Validation of Inhalation Provocation Test in Chronic Bird-Related Hypersensitivity Pneumonitis and New Prediction Score. Ann Am Thorac Soc. 2014 ; 12 : 167-73.

5) Nakashima R, et al. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016 ; 25 : 925-33.

6) Tanizawa K, et al. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respir Med. 2017 : 127 : 57-64.

P.168 掲載の参考文献

1) 日本分子腫瘍マーカー研究会 (編). 分子腫瘍マーカー診療ガイドライン第1版. 東京 : 金原出版 ; 2016.

2) 日本肺癌学会 (編). EBMの手法による肺癌診療ガイドライン 2016年版. 東京 : 金原出版 ; 2016.

3) Okada M, et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer : analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg. 2004 Jul ; 78 (1) : 216-21.

4) Nomura F, et al. Serum levels of five tumor markers for lung cancer in patients with chronic renal failure. Oncol Rep. 1998 Mar-Apr ; 5 (2) : 389-92.

5) Fujita J, et al. Elevation of cytokeratin 19 fragment (CYFRA 21-1) in serum of patients with radiation pneumonitis : possible marker of epithelial cell damage. Respir Med. 2004 Apr ; 98 (4) : 294-300.

6) Harmsma M, et al. Serum markers in small cell lung cancer : opportunities for improvement. Biochim Biophys Acta. 2013 Dec ; 1836 (2) : 255-72.

7) Zhao WX, et al. Serum neuron-specific enolase levels were associated with the prognosis of small cell lung cancer : a meta-analysis. Tumour Biol. 2013 Oct ; 34 (5) : 3245-8.

8) Hirose T, et al. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer? Lung Cancer. 2011 Feb ; 71 (2) : 224-8.

9) Hollevoet K, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma : an individual patient data meta-analysis. J Clin Oncol. 2012 May 1 ; 30 (13) : 1541-9.

10) Pass HI, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005 Oct 13 ; 353 (15) : 1564-73.

11) Pass HI, et al. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. J Thorac Oncol. 2016 Jun ; 11 (6) : 900-9.

P.173 掲載の参考文献

1) 日本肺癌学会バイオマーカー委員会 (編). 肺癌患者におけるEGFR遺伝子変異検査の手引き第3.05版. 2016. https://www.haigan.gr.jp/uploads/photos/1329.pdf

2) Mok TS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 ; 947-57.

3) Fukuoka M, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced nonsmall-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011 ; 29 : 2866-74.

4) 日本肺癌学会バイオマーカー委員会 (編). 肺癌患者におけるALK融合遺伝子検査の手引き第2.1版. 2015. https://www.haigan.gr.jp/uploads/photos/1039.pdf

5) 日本肺癌学会バイオマーカー委員会 (編). 肺癌患者におけるROS1融合遺伝子検査の手引き第1.0版. 2017. https://www.haigan.gr.jp/uploads/photos/1398.pdf

6) 日本肺癌学会バイオマーカー委員会 (編). 肺癌患者におけるPD-L1検査の手引き第1.0版. 2017. https://www.haigan.gr.jp/uploads/photos/1400.pdf

7) 日本肺癌学会バイオマーカー委員会 (編). 肺癌患者におけるBRAF遺伝子変異検査の手引き第1.0版. 2018. https://www.haigan.gr.jp/uploads/photos/1620.pdf

8) 金田安史, 他. ゲノム情報と遺伝子治療-遺伝子治療の最新動向-. 日本臨床. 2017 ; 75 (5) : 660-814.

9) Choi M, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci USA. 2009 ; 106 : 19096-101.

10) 遺伝子診断と生命倫理を考える. 日本医事新報. 2016 ; 4836 : 18-31.

11) Rafeeq MM, et al. Cystic fibrosis : current therapeutic targets and future approaches. J Trans Med. 2017 ; 15 : 1-9.

12) Lai M, et al. Gene editing of DNAH11 restores normal cilia motility in primary ciliary dyskinesia. J Med Genet. 2016 ; 53 : 242-9.

P.176 掲載の参考文献

1) Pin I, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax. 1992 Jan ; 47 (1) : 25-9.

2) Rao GN, et al. Induced sputum versus bronchial washings in the diagnosis of sputum negative pulmonary tuberculosis. J Family Med Prim Care. 2016 Apr-Jun ; 5 (2) : 435-9.

3) 川田博, 他. 高張食塩水吸入誘発痰による肺結核の診断-従来法と核酸増幅法の比較-. 日呼吸会誌. 1998 ; 36 (11) : 959-62.

4) Miller DL. A STUDY OF TECHNIQUES FOR THE EXAMINATION OF SPUTUM IN A FIELD SURVEY OF CHRONIC BRONCHITIS. Am Rev Respir Dis. 1963 Oct ; 88 : 473-83.

5) Aberle DR, et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med. 2013 Sep 5 ; 369 (10) : 920-31.

6) National Lung Screening Trial Research Team. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013 May 23 ; 368 (21) : 1980-91.

7) Sing A, et al. Comparison of the sensitivity of sputum and brush cytology in the diagnosis of lung carcinomas. Acta Cytol. 1997 Mar-Apr ; 41 (2) : 399-408.

8) Doria-Rose VP, et al. Randomized controlled trials of the efficacy of lung cancer screening by sputum cytology revisited : a combined mortality analysis from the Johns Hopkins Lung Project and the Memorial Sloan-Kettering Lung Study. Cancer. 2009 Nov 1 ; 115 (21) : 5007-17.

9) 日本肺癌学会 (編). EBMの手法による肺癌診療ガイドライン 2016年版. 東京 : 金原出版 ; 2016.

10) 日本肺癌学会 (編). 臨床・病理肺癌取り扱い規約 (第7版). 東京 : 金原出版 ; 2016.

P.181 掲載の参考文献

1) 伊藤功朗. 肺炎の診かた, 考えかた. 東京 : 中外医学社 ; 2016.

2) Fukuyama H, et al. Validation of sputum Gram stain for treatment of community-acquired pneumonia and healthcare-associated pneumonia : a prospective observational study. BMC Infect Dis. 2014 : 14 ; 534.

3) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会 (編). 成人肺炎診療ガイドライン 2017. 2017.

4) Ishida T, et al. Efficacy of transthoracic needle aspiration in community-acquired pneumonia. Intern Med. 2001 ; 40 : 873-7.

5) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会 (編). 成人院内肺炎診療ガイドライン. 2008.

6) Pfeiffer CD, et al. Diagnosis of invasive aspergillosis using a galactomannan assay : a meta-analysis. Clin Infect Dis. 2006 ; 42 : 1417-27.

P.183 掲載の参考文献

1) 大畑正昭. 日本気管支学会のあゆみ (第20回日本気管支学会総会). 気管支学. 1997 ; 19 (8) : 611-20.

2) 雨宮隆太, 他. 気管支鏡の歴史気管支ファイバースコープを中心に. 気管支学. 2013 ; 35 : 435-47

3) Patterson EJ. History of bronchoscopy and esophagoscopy for foreign body. Laryngoscope. 1926 ; 36 (3) : 157-75.

4) Haas AR, et al. Advances in diagnostic bronchoscopy. Am J Respir Crit Care Med. 2010 ; 182 (5) : 589-97.

P.190 掲載の参考文献

1) 藤本一眞, 他. 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. 日本消化器内視鏡学会雑誌. 2012 ; 54 (7) : 2073-102.

2) Du Rand IA, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults. Thorax. 2013 ; 68 : i1-i44.

3) 日本呼吸器内視鏡学会安全対策委員会 (編). 手引書-呼吸器内視鏡診療を安全に行うために- (Ver. 3.0). 2013.

4) 宮澤輝臣, 他. 気管支鏡ベストテクニック. 東京 : 中外医学社 ; 2017.

P.192 掲載の参考文献

1) 浅野文祐, 他. 気管支鏡ベストテクニック第2版. 東京 : 中外医学社 ; 2012.

2) Kramer TA, et al. Tracheobronchial and esophageal foreign bodies in the pediatric population. J Otolaryngol. 1989 ; 15 : 355.

3) Haliloglu, et al. CT virtual bronchoscopy in the evaluation of children with suspected foreign body aspiration. Eur J Radiol. 2003 ; 48 : 188-92.

P.195 掲載の参考文献

1) Meyer KC, et al. An official American Thoracic Society clinical practice guideline : the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012 ; 185 : 1004-14.

2) The BAL Cooperative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis. 1990 ; 141 : S169.

3) Kilinc G, et al. The role of bronchoalveolar lavage in diffuse parenchymal lung diseases. Curr Opin Pulm Med. 2005 ; 11 : 417-21.

4) Babiak A, et al. Transbronchial cryobiopsy : a new tool for lung biopsies. Respiration. 2009 ; 78 : 203-8.

P.199 掲載の参考文献

1) Yasufuku K, et al. Real-time Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration of Mediastinal and Hilar Lymph Nodes. Chest. 2004 ; 126 : 122-8.

2) Silvestri GA, et al. Methods for Staging Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013 ; 143 : e211S-50S.

3) Kayawake H, et al. Complications of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. Ann Thorac Surg. 2017 Nov ; 104 (5) : e363-e365.

4) Chen F, et al. Usefulness of endobronchial ultrasound in patients with previously treated thoracic malignancy. Interact Cardiovasc Thorac Surg. 2012 ; 14 : 34-7.

5) Chen-Yoshikawa TF, et al. Update on three-dimensional image reconstruction for preoperative simulation in thoracic surgery. J Thorac Dis. 2016 ; 8 : S295-301.

P.203 掲載の参考文献

1) Kurimoto N, et al. Endobronchial ultrasonography using a guide sheath increases the ability to diagnose peripheral pulmonary lesions endoscopically. Chest. 2004 ; 126 : 959-65.

2) Ishida T, et al. Virtual bronchoscopic navigation combined with endobronchial ultrasound to diagnose small peripheral pulmonary lesions : a randomised trial. Thorax. 2011 ; 66 : 1072-7.

3) Yamada N, et al. Factors related to diagnostic yield of transbronchial biopsy using endobronchial ultrasonography with a guide sheath in small peripheral pulmonary lesions. Chest. 2007 ; 132 : 603-8.

4) Steinfort DP, et al. Radial probe endobronchial ultrasound for the diagnosis of peripheral lung cancer : systematic review and meta-analysis. Eur Respir J. 2011 ; 37 : 902-10.

5) Hayama M, et al. Complications with Endobronchial Ultrasound with a Guide Sheath for the Diagnosis of Peripheral Pulmonary Lesions. Respiration. 2015 ; 90 : 129-35.

P.207 掲載の参考文献

1) Dalrymple NC, et al. Informatics in radiology (infoRAD) : introduction to the language of three-dimensional imaging with multidetector CT. Radiographics. 2005 Sep-Oct ; 25 (5) : 1409-28.

2) Barnes D, et al. Central airway pathology : clinic features, CT findings with pathologic and virtual endoscopy correlation. Insights Imaging. 2017 Apr ; 8 (2) : 255-70.

3) Asano F, et al. Virtual bronchoscopic navigation for peripheral pulmonary lesions. Respiration. 2014 ; 88 (5) : 430-40.

4) Goud A, et al. Role of electromagnetic navigational bronchoscopy in pulmonary nodule management. J Thorac Dis. 2016 Jul ; 8 (Suppl 6) : S501-8.

P.214 掲載の参考文献

1) Dougherty TJ, et al. Photodynamic therapy. J Natl Cancer Inst. 1998 ; 90 : 889-905.

2) 日本レーザー医学会安全委員会. 早期肺癌を対象としたPDT施行の安全ガイドライン. 日本レーザー医学会誌. 2011. 32. supp 1 : 1-4.

3) Kato H, et al. Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer. 2003 ; 42 : 103-11.

4) Ikeda N, et al. New aspects of photodynamic therapy for central type early stage lung cancer. Lasers Surg Med. 2011 ; 43 : 749-54.

5) レザフィリン(R) PDT施行ハンドブック食道癌・肺癌編.

P.218 掲載の参考文献

1) Hooper C, et al. BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults : British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010 ; 65 Suppl 2 : ii4-17.

P.221 掲載の参考文献

1) 日本肺癌学会 (編). EBMの手法による肺癌診療ガイドライン 2016年版. 東京 : 金原出版 ; 2016.

2) 肺生検研究会 (編). 肺生検研究会ステートメント. IVR会誌. 2007 ; 22 : 256-61.

3) Fassina A, et al. Role and accuracy of rapid on-site evaluation of CT-guided fine needle aspiration cytology of lung nodules. Cytopathology. 2011 Oct ; 22 (5) : 306-12.

4) Tomiyama N, et al. CT-guided needle biopsy of lung lesions : a survey of severe complication based on 9783 biopsies in Japan. Eur J Radiol. 2006 Jul ; 59 (1) : 60-4.

5) Heerink WJ, et al. Complication rates of CT-guided transthoracic lung biopsy : meta-analysis. Eur Radiol. 2017 ; 27 (1) : 138-48.

P.225 掲載の参考文献

1) Zakkar M, et al, Hunt I. Is video mediastinoscopy a safer and more effective procedure than conventional mediastinoscopy? Interact Cardiovasc Thorac Surg. 2012 ; 14 : 81-4.

2) De Leyn P, Dooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014 ; 45 : 787-98.

P.227 掲載の参考文献

1) Sonobe M, et al. Videothoracoscopy-assisted surgical lung biopsy for interstitial lung diseases. Gen Thorac Cardiovasc Surg. 2014 ; 62 : 376-82.

P.231 掲載の参考文献

1) Hoksch B, et al. Thoracoscopy before Jacobaeus. Ann Thorac Surg. 2002 ; 74 (4) : 1288-90.

2) Sonobe M, et al. Videothoracoscopy-assisted surgical lung biopsy for interstitial lung diseases. Gen Thorac Cardiovasc Surg. 2014 ; 62 (6) : 376-82.

3) 日本肺癌学会. 肺癌診療ガイドライン. 2016.

4) Committee for Scientific Affairs TJAfTS, et al. Thoracic and cardiovascular surgery in Japan during 2014 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2016 ; 64 (11) : 665-97.

P.233 掲載の参考文献

1) 工藤翔二, 他 (編). 呼吸器専門医テキスト. 東京 : 南江堂 ; 2007.

2) 日本外傷学会初期診療ガイドライン改訂第5版編集委員会 (編). 外傷初期診療ガイドラインJATEC 改訂第5版. 東京 : へるす出版 ; 2016.

3) Alrajhi, et al. Test characteristics of ultrasonography for the detection of pneumothorax. a systematic review and meta-analysis. Chest. 2012 Mar ; 141 (3) : 703-8.

P.235 掲載の参考文献

1) 工藤翔二, 他 (編). 呼吸器専門医テキスト. 東京 : 南江堂 ; 2007.

2) Nair AS, et al. Electrocardiographic changes after lung resection : Case report and brief review. Anesth Essays Res. 2015 May-Aug ; 9 (2) : 263-5.

3) Muranishi Y, et al. Atrial fibrillation after lung cancer surgery : incidence, severity, and risk factors. Surg Today. 2017 Feb ; 47 (2) : 252-8.

P.237 掲載の参考文献

1) Murphy RL Jr, et al. Visual lung-sound characterization by time-expanded wave-form analysis. N Engl J Med. 1977 ; 296 : 968-71.

2) Nagasaka Y. Lung sounds in bronchial asthma. Allergol Int. 2012 ; 61 : 353-63.

3) 中野博 (編著). 肺聴診エキスパート. 東京 : リブロ・サイエンス ; 2015. pp. 183-95.

4) Piirila P, et al. Crackles : Recording, analysis and clinical significance. Eur Respir J. 1995 ; 8 : 2139-48.

5) Tsuchiya M, et al. Sound spectrographic characteristics of fine and coarse crackles. The 39th Meeting of International Lung Sound Association. Boston 2014. http://www.ilsaus.com/pdf/39th_ILSA_2014.pdf.

6) 長坂行雄. 肺の聴診 (2) 断続性ラ音と胸膜摩擦音. 呼吸器ジャーナル. 2017 ; 65 : 354-9.

P.242 掲載の参考文献

1) 日本呼吸器学会肺生理専門委員会, 日本呼吸管理学会酸素療法ガイドライン作成委員会 (編). 酸素療法ガイドライン. 東京 : メディカルレビュー社 ; 2006.

2) Kallstrom TJ. American Association for Respiratory Care (AARC). AARC Clinical Practice Guideline : oxygen therapy for adults in the acute care facility-2002 revision & update. Respir Care. 2002 ; 47 : 717-20.

3) 陳和夫. 酸素療法. 3学会合同呼吸療法認定士認定委員会 (編). 新呼吸療法テキスト. 東京 : アトムス ; 2012, p.155-68.

4) 富井啓介. 高流量鼻カニュラ酸素療法 (ネーザルハイフロー). 日本呼吸ケアリハ学誌. 2016 ; 26 : 21-5.

5) 陳和夫. 酸素療法と非侵襲的換気. 日本呼吸ケアリハ学誌. 2015 ; 25 : 168-73.

P.252 掲載の参考文献

1) 日本呼吸器学会 NPPVガイドライン作成委員会. NPPV (非侵襲的陽圧換気療法) ガイドライン (改訂第2版). 2015.

2) 坪井知正, 他. 肺結核後遺症における急性期 NPPVの治療成績. 日呼吸会誌. 2006 ; 44 : 160-7.

3) Tsuboi T, et al. Importance of ventilator mode in long-term noninvasive positive pressure ventilation. Respir Med. 2009 ; 103 : 1854-61.

4) Kohnlein T, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease : a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med. 2014 ; 2 (9) : 698-705.

5) Murphy PB, et al. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation : A Randomized Clinical Trial. JAMA. 2017 Jun 6 ; 317 (21) : 2177-86.

P.256 掲載の参考文献

1) 一般社団法人日本蘇生協議会. JRC蘇生ガイドライン 2015. 東京 : 医学書院 ; 2016.

2) ACLSプロバイダーマニュアル AHAガイドライン 2015準拠. American Heart Association. シナジー ; 2017.

P.259 掲載の参考文献

1) Esteban A, et al. How is mechanical ventilation employed in the intensive care unit? An international utilization review. Am J Respir Crit Care Med. 2000 May ; 161 (5) : 1450-8.

2) Young D, et al. Effect of early vs late tracheostomy placement on survival in patients receiving mechanical ventilation : the TracMan randomized trial. JAMA. 2013 May 22 ; 309 (20) : 2121-9.

3) Futran ND, et al. The safety and efficacy of bedside tracheotomy. Otolaryngol Head Neck Surg. 1993 Oct ; 109 (4) : 707-11.

4) Sataloff RT. Clinical consensus statement : tracheostomy care. Otolaryngol Head Neck Surg. 2013 Jul ; 149 (1) : 174.

5) O'Connor HH, et al. Tracheostomy decannulation. Respir Care. 2010 Aug ; 55 (8) : 1076-81.

P.268 掲載の参考文献

1) Roux E, et al. Muscarinic stimulation of airway smooth muscle cells. Gen Pharmacol. 1998 Sep ; 31 (3) : 349-56.

2) Ikeda A, et al. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD : comparison with ipratropium bromide alone. Chest. 1995 ; 107 : 401-5.

3) Ikeda T, et al. Regional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airways. Br J Pharmacol. 2012 ; 166 : 1804-14.

4) 日本呼吸器学会COPDガイドライン第4版作成委員会 (編). COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第4版. 東京 : メディカルレビュー社 ; 2013.

5) 日本呼吸器学会COPDガイドライン第5版作成委員会 (編). COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第5版 2018. 東京 : メディカルレビュー社 ; 2018.

6) Wedzicha JA, et al ; FLAME Investigators. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016 ; 374 : 2222-34.

7) Vogelmeier CF, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017 ; 195 : 557-82.

8) 喘息予防・管理ガイドライン2015作成委員. 日本アレルギー学会喘息ガイドライン専門部会 (監). 喘息予防・管理ガイドライン 2015. 東京 : 協和企画 ; 2015.

9) Tashkin DP, et al ; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 ; 359 : 1543-54.

10) Grainge CL, et al. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med. 2011 ; 364 : 2006-15.

11) Kistemaker LEM, et al. Acetylcholine beyond bronchoconstriction : roles in inflammation and remodeling. Trends Pharmacol Sci. 2015 ; 36 : 164-71.

P.270 掲載の参考文献

1) 日本呼吸器学会咳嗽に関するガイドライン第2版作成委員会 (編). 咳嗽に関するガイドライン第2版. 2012.

2) 日本呼吸器学会COPD ガイドライン第4版作成委員会 (編). COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第4版. 2013.

3) Niimi A, et al. Impaired cough reflex in patients with recurrentpneumonia. Thorax. 2003 ; 58 : 152-3.

4) Sekizawa K, et al. ACE inhibitors and pneumonia. Lancet. 1998 ; 352 : 1069.

P.278 掲載の参考文献

1) Smoak KA, et al. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev. 2004 ; 125 : 697-706.

2) 喘息予防・管理ガイドライン2012作成委員 (編). 喘息予防・管理ガイドライン 2012. 東京 : 協和企画 ; 2012.

3) 日本呼吸器学会COPDガイドライン第5版作成委員会 (編). COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第5版 2018. 東京 : メディカルレビュー社 ; 2018.

4) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会 (編). 特発性間質性肺炎診断と治療の手引き改訂第3版. 東京 : 南江堂 ; 2016.

5) Liu D, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013 ; 9 : 30.

P.281 掲載の参考文献

1) 「喘息予防・管理ガイドライン 2015」作成委員 (編). 喘息予防・管理ガイドライン 2015. 東京 : 協和企画 ; 2015.

2) 川島眞, 他. 鎮静性および非鎮静性抗ヒスタミン薬のかゆみ抑制効果と眠気の発現に関する比較検討 (ACROSS trial) 臨床医薬. 2011 ; 27 (8) : 563-73.

3) 鼻アレルギー診療ガイドライン作成委員会 (編). 鼻アレルギー診療ガイドライン-通年性鼻炎と花粉症-2016年版. 東京 : ライフ・サイエンス ; 2016.

P.290 掲載の参考文献

1) Suzuki M, et al. A Randomized, Placebo-controlled trial of acupuncture in patients with chronic obstructive pulmonary disease (COPD). Arch Intern Med. 2012 ; 172 : 878-86.

P.295 掲載の参考文献

1) 日本肺癌学会 (編). 肺癌診療ガイドライン2018年版悪性胸膜中皮腫・胸腺腫瘍含む. 東京 : 金原出版 ; 2018.

2) 日本イーライリリー株式会社. アリムタ注射用100mg/アリムタ注射用500mg. 医薬品インタビューフォーム 2015年1月 (第10版). 2015.

3) Socinski MA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer : final results of a phase III trial. J Clin Oncol. 2012 ; 30 : 2055-62.

4) Ando Y, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity : a pharmacogenetic analysis. Cancer Res. 2000 ; 15 : 6921-6.

P.298 掲載の参考文献

1) Rivers E, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 ; 345 (19) : 1368-77.

2) Wiedemann HP, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006 ; 354 (24) : 2564-75.

3) Martin GS, et al. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med. 2002 ; 30 (10) : 2175-82.

4) Askanazi J, et al. Nutrition for the patient with respiratory failure : glucose vs. fat. Anesthesiology. 1981 ; 54 (5) : 373-7.

P.300 掲載の参考文献

1) Ventricular failure. In : The Criteria Committee of the New York Heart Association, editor. Nomenclature and Criteria foe Diagnosis of Disease of the Heart and Great Vessels. 8th ed. Boston : Little Brown ; 1979. pp. 268-72.

2) Wiig H, et al. Interstitial fluid pressure in the isolated perfused rabbit lung. Acta Physiol Scand. 1985 ; 125 : 601-7.

3) The Jugular Pulse. In : Constant J, editor. Bedside Cardiology 2nd ed. Boston : Little Brown ; 1976. pp. 69-99.

4) 長坂行雄. スターリング曲線とスターリングの式 (equation). 呼吸器ジャーナル. 2017 ; 3 : 518-25.

P.306 掲載の参考文献

1) Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery. Thoracic and cardiovascular surgery in Japan during 2014 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2016 ; 64 : 665-97.

P.313 掲載の参考文献

1) Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery. Thoracic and cardiovascular surgery in Japan during 2014 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2016 ; 64 : 665-97.

2) Sato M, et al. Use of virtual assisted lung mapping (VALMAP), a bronchoscopic multispot dye-marking technique using virtual images, for precise navigation of thoracoscopic sublobar lung resection. J Thorac Cardiovasc Surg. 2014 ; 147 : 1813-9.

3) Okada M, et al. A novel video-assisted anatomic segmentectomy technique : selective segmental inflation via bronchofiberoptic jet followed by cautery cutting. J Thorac Cardiovasc Surg. 2007 ; 133 : 753-8.

P.315 掲載の参考文献

1) Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery. Thoracic and cardiovascular surgery in Japan during 2014 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2016 ; 64 : 665-97.

2) Sato M, et al. Use of virtual assisted lung mapping (VALMAP), a bronchoscopic multispot dye-marking technique using virtual images, for precise navigation of thoracoscopic sublobar lung resection. J Thorac Cardiovasc Surg. 2014 ; 147 : 1813-9.

P.318 掲載の参考文献

1) Grunenwald D, et al. Transmanubrial osteomuscular sparing approach for apical chest tumors. Ann Thorac Surg. 1997 ; 63 : 563-6.

2) 城戸哲夫, 他. 症筋無力症患者連続110例に対する内視鏡下拡大胸腺摘出術の遠隔治療成績. 日呼外会誌. 2007 ; 22 : 2-7.

3) 塩野裕之, 他. 内視鏡下胸腺摘出術に関する全国調査-日本胸腺研究会アンケート調査報告-. 日呼外会誌. 2007 ; 21 : 17-21.

4) Nakamura H, et al. First experience of robotic extended thymectomy in Japan for myasthenia gravis with thymoma. Gen Thorac Cardiovasc Surg. 2012 ; 60 : 183-7.

5) Ruckert JC, et al. Comparison of robotic and nonrobotic thoracoscopic thymectomy : A cohort study. J Thorac Cardiovasc Surg. 2011 ; 141 : 673-7.

P.321 掲載の参考文献

1) Chen F, et al. Complete resection of a giant mediastinal leiomyosarcoma. Ann Thorac Surg. 2015 ; 99 : e69-71.

P.324 掲載の参考文献

1) Cooper JD, et al. Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema. J Thorac Cardiovasc Surg. 1996 ; 112 : 1319-29.

2) National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med. 2001 ; 345 : 1075-83.

3) National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003 ; 348 : 2059-73.

4) Naunheim KS, et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg. 2006 ; 82 : 431-43.

5) Date H, et al. Bilateral lung volume reduction surgery via median sternotomy for severe pulmonary emphysema Ann Thorac Surg. 1998 ; 65 : 939-42.

P.327 掲載の参考文献

1) Toronto Lung Transplant Group. Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med. 1986 ; 314 : 1140-5.

2) Patterson GA, et al. Experimental and clinical double lung transplantation. J Thorac Cardiovasc Surg. 1988 ; 95 : 70-4.

3) Starnes VA, et al. A decade of living lobar lung transplantation. Recipient outcomes. J Thorac Cardiovasc Surg. 2004 ; 127 : 114-22.

4) Chambers DC, et al. Registry of the International Society for Heart and Lung Transplantation : Thirty-fourth adult lung and heart-lung transplant report-2017 : Focus Theme : Allograft ischemic time. J Heart Lung Transplant. 2017 ; 36 : 1047-59.

5) Date H, et al. Living-donor lobar lung transplantation for primary ciliary dyskinesia. Ann Thorac Surg. 2001 ; 71 : 2008-9.

6) Date H. Current status and problem of lung transplantation in Japan. J Thorac Dis. 2016 ; 8 (Suppl 8) : S631-6.

7) Date H. Living-related lung transplantation. J Thorac Dis. 2017 ; 9 : 3362-71.

P.332 掲載の参考文献

1) 肺移植関連学会協議会. 肺移植レシピエントの適応基準. 2015. http://www2.idac.tohoku.ac.jp/dep/surg/shinpai/pg348.html, (accessed 2018-08-26)

2) Date H. Current status and problem of lung transplantation in Japan. J Thorac Dis. 2016 ; 8 (Suppl 8) : S631-6.

3) Chen-Yoshikawa TF, et al. Prognostic factors in lung transplantation after hematopoietic stem cell transplantation. Transplantation. 2018 ; 102 : 154-61.

4) Weill D, et al. A consensus document for the selection of lung transplant candidates : 2014-An update from the pulmonary transplantation council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015 ; 34 : 1-15.

5) Date H. Lung transplantation. In : Fukumoto Y, ed. Diagnosis and treatment of pulmonary hypertension. Berlin : Springer ; 2017. pp.171-82.

6) Motoyama H, et al. Quantitative evaluation of native lung hyperinflation after lung transplantation for emphysema using three-dimensional computed tomography volumetry. Transplant Proc. 2014 ; 46 : 941-3.

7) Date H, et al. Living-donor lobar lung transplantation for primary ciliary dyskinesia. Ann Thorac Surg. 2001 ; 71 : 2008-9.

P.338 掲載の参考文献

1) Date H, et al. Living-donor lobar lung transplantation for various lung diseases. J Thorac Cardiovasc Surg. 2001 ; 126 : 476-81.

2) 佐藤雅昭, 他. 生体肺移植ドナー手術手技の工夫. 日呼外会誌. 2014 ; 28 (4) : 21-7.

P.342 掲載の参考文献

1) Division of Transplantation, Bureau of Health Resources Development. 2012 annual data report of the US Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network.

2) 日本臓器移植ネットワーク. [https://www.jotnw.or.jp]

3) Sundaresan S, et al. Donor lung procurement : assessment and operative technique. Ann Thorac Surg. 1993 ; 56 : 1409-13.

4) 星川康. 日本移植学会 (編). 肺採取術マニュアル. [www.asas.or.jp/jst/pdf/manual/004.pdf]

P.346 掲載の参考文献

1) Chen F, et al. Postoperative respiratory management in living donor lobar lung transplantation. Clin Transplant. 2013 ; 27 : E383-90.

2) Yusen RD, et al. The Registry of the International Society for Heart and Lung Transplantation : Thirty-second Official Adult Lung and Heart-Lung Transplantation Report-2015 ; Focus Theme : Early Graft Failure. J Heart Lung Transplant. 2015 ; 34 : 1264-77.

3) Takahashi K, et al. Single-lobe lung transplantation for rapidly deteriorating pulmonary veno-occlusive disease Ann Thorac Surg. 2013 ; 95 : 689-91.

4) Chen F, et al. Gastroparesis after living-donor lobar lung transplantation. Report of 5 cases. Surg Today. 2015 ; 45 : 378-82.

5) Chen F, et al. Prognostic factors in lung transplantation after hematopoietic stem cell transplantation. Transplantation 2017 Jul 21. doi : 10.1097/TP.0000000000001886. [Epub ahead of print]

6) Miyamoto E, et al. Stenosis of the segmental bronchus is a characteristic airway complication in living-donor lobar lung transplantation. J Heart Lung Transplant. 2016 ; 35 : 389-92.

P.350 掲載の参考文献

1) 日本放射線腫瘍学会放射線腫瘍学データセンター. 放射線治療施設構造調査の解析結果. http://www.jastro.or.jp/aboutus/datacenter.php

2) 国立がん研究センターがん情報サービス. がん登録・統計. 2017. http://ganjoho.jp/reg_stat/ [参照 2017年5月22日]

3) 全国がん (成人病) センター協議会. 全がん協生存率調査. http://www.zengankyo.ncc.go.jp/etc/index.html

P.353 掲載の参考文献

1) Basic Clinical Radiobiology. 4th ed. Joiner M, van der Kogel A, editors. Flonda : CRC Press ; 2009.

2) 日本放射線腫瘍学会, 日本放射線腫瘍学研究機構 (編). 臨床放射線腫瘍学. 東京 : 南江堂 ; 2012.

3) Yeom CJ, et al. Strategies to Assess Hypoxic/HIF-1-Active Cancer Cells for the Development of Innovative Radiation Therapy. Cancers (Basel). 2011 ; 3 (3) : 3610-31.

P.357 掲載の参考文献

1) Varian. https://www.varian.com/oncology/products/treatment-delivery/truebeam-radiotherapy-system. (accessed 2017-08-01)

2) Medical Equipment Technology, Support and Management. http://its.uvm.edu/medtech/module.html. (accessed 2017-08-01)

3) International Commission on Radiation Units and Measurements (ICRU) Report 50 : Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda : 1993.

4) International Commission on Radiation Units and Measurements (ICRU) Report 62 : Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). Washington D. C. : 1999.

P.366 掲載の参考文献

1) 日本呼吸ケア・リハビリテーション学会, 日本呼吸理学療法学会, 日本呼吸器学会. 呼吸リハビリテーションに関するステートメント. 日呼吸ケアリハ会誌. 2018 ; 27 (2) : 95-114.

2) 木田厚瑞. 包括的呼吸リハビリテーション-チーム医療のためのマニュアル. 東京 : メディカルレビュー社 ; 1998

3) 日本呼吸器学会COPDガイドライン第4版作成委員会 (編). COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第4版. 東京 : メディカルレビュー社 ; 2013.

4) Global Initiative for Chronic Obstructive Lung Disease. Gold 2011 Global Strategy for the Diagnosis. Management and Prevention of COPD. 2011. http://goldcopd.org

5) Global Initiative for Chronic Obstructive Lung Disease. Gold 2016 Global Strategy for the Diagnosis. Management and Prevention of COPD. 2016. http://goldcopd.org

6) 玉木彰 (編). DVDで学ぶ呼吸理学療法テクニック-呼吸と手技のタイミングがわかる動画 91. 東京 : 南江堂 ; 2008.

7) 日本集中治療医学会早期リハビリテーション検討委員会. 集中治療における早期リハビリテーション～根拠に基づくエキスパートコンセンサス～. 日集中医誌. 2017 ; 24 : 255-303.

8) McCarthy B, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015 ; 2 : CD003793.

P.371 掲載の参考文献

1) 中村正和. FCTC14条禁煙支援・治療. 保健医療科学. 2015 ; 64 (5) : 475-83.

2) Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence : 2008 update. A U.S. Public Health Service report. Am J Prev Med. 2008 ; 35 (2) : 158-76.

3) 厚生労働省健康局健康課 (編). 禁煙支援マニュアル (第二版) 増補改訂版. 2018. https://www.mhlw.go.jp/topics/tobacco/kin-en-sien/manual2/dl/addition01.pdf

4) 日本循環器学会, 他 (編). 禁煙治療のための標準手順書第6版. 2014. http://www.j-circ.or.jp/kinen/anti_smoke_std/pdf/anti_smoke_std_rev6.pdf

5) Kawakami N, et al. Development of a screening questionnaire for tobacco/nicotine dependence according to ICD-10, DSM-III-R, and DSM-IV. Addict Behav. 1999 ; 24 (2) : 155-66.

6) Stead LF, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012 ; 11 : CD000146.

7) Cahill K, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016 ; (5) : CD006103.

8) Hartmann-Boyce J, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018 ; 5 : CD000146.

9) 一般社団法人日本禁煙学会禁煙治療と支援委員会. 若年者の禁煙治療指針. 禁煙会誌. 2016 ; 11 (6) : 145.

10) Prochaska JJ. Smoking and mental illness--breaking the link. N Engl J Med. 2011 ; 365 (3) : 196-8.

P.375 掲載の参考文献

1) 日本アレルギー学会. ダニアレルギーにおけるアレルゲン免疫療法の手引き. 東京 : メディカルレビュー ; 2015.

2) 海老澤元宏. アレルゲン回避の意義と指導の実際. アレルギー. 2008 ; 57 : 1-8.

3) 永田真. 成人内科領域のアレルゲン免疫療法. アレルギー. 2015 ; 64 : 781-6.

4) Chelladurai Y, et al. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma : a systematic review. J Allergy Clin Immunol Pract. 2013 ; 1 : 361-9.

5) 日本アレルギー学会. スギ花粉症におけるアレルゲン免疫療法の手引き. 東京 : メディカルレビュー ; 2013.

P.380 掲載の参考文献

1) Nichol KL, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007 ; 357 (14) : 1373-81.

2) Tessmer A, et al. Influenza vaccination is associated with reduced severity of community-acquired pneumonia. Eur Respir J. 2011 ; 38 (1) : 147-53.

3) Osterholm MT, et al. Efficacy and effectiveness of influenza vaccines : a systematic review and meta-analysis. Lancet Infect Dis. 2012 ; 12 (1) : 36-44.

4) Bonten MJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015 ; 372 (12) : 1114-25.

5) 日本呼吸器学会, 日本感染症学会合同委員会 (編). 65歳以上の成人に対する肺炎球菌ワクチン接種に関する考え方. 2015.

P.384 掲載の参考文献

1) 日本呼吸ケア・リハビリテーション学会酸素療法マニュアル作成委員会日本呼吸器学会肺生理専門委員会 (編). 酸素療法マニュアル (酸素療法ガイドライン改訂版). 東京 : メディカルレビュー社 ; 2018.

2) 日本呼吸器学会肺生理専門委員会在宅呼吸ケア白書ワーキンググループ. 在宅呼吸ケア白書. 2010.

3) Managing stable COPD. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and second care. The national collaborating centre for chronic conditions. Thorax. 2004 ; 59 : 39-130.

4) 日本呼吸器学会COPDガイドライン第4版作成委員会 (編). COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第4版. 東京 : メディカルレビュー社 ; 2013.

5) 日本呼吸器学会 (編). NPPV (非侵襲的陽圧換気療法) ガイドライン (改訂第2版). 東京 : 南江堂 ; 2015.

6) Albert RK, et al ; Long-Term Oxygen Treatment Trial Research Group. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med. 2016 ; 375 : 1617-27.

7) Harris-Eze AO, et al. Oxygen improves maximal exercise performance in interstitial lung disease. Am J Respir Crit Care Med. 1994 ; 150 : 1616-22.

P.387 掲載の参考文献

1) Sullivan CE, et al. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet. 1981 ; 1 : 862-5.

2) 医科点数表の解釈平成28年4月版. 東京 : 社会保険研究所 ; 2016

3) 日本呼吸器学会 (編). NPPV (非侵襲的陽圧換気療法). ガイドライン (改訂第2版) 東京 : 南江堂 ; 2015.

4) 福原俊一, 他. 日本語版the Epworth Sleepiness Scale (JESS) ～これまで使用されてきた多くの「日本語版」との主な差異と改訂～. 日呼吸会誌. 2006 ; 44 : 897-8.

P.391 掲載の参考文献

1) 日本呼吸器学会NPPV ガイドライン作成委員会 (編). NPPV (非侵襲的陽圧換気療法) ガイドライン (改訂第2版). 東京 : 南江堂 ; 2015.

2) 社会保険研究所. 医科点数表の解釈平成26年4月版.

3) 日本呼吸器学会肺生理専門委員会在宅呼吸ケア白書ワーキンググループ (編). 在宅呼吸ケア白書 2010. 東京 : 日本呼吸器学会 ; 2010.

4) 大井元晴, 他. 睡眠時呼吸異常. 日本胸部臨床. 1984 ; 43 : 7-14.

P.396 掲載の参考文献

1) 志真泰夫, 他. 緩和ケアの歴史と展望. 日本緩和医療学会 (編). 専門家をめざす人のための緩和医療学第1版. 東京 : 南江堂, 2014. pp.2-10.

2) 厚生労働省. がん対策推進基本計画. http://www.mhlw.go.jp/bunya/kenkou/gan_keikaku.html, (閲覧 : 2017-07-30)

3) Wenk R, et al (eds). Pallipedia. http://pallipedia.org/, (閲覧 : 2017-07-30)

4) 日本緩和医療学会. 厚生労働省委託PEACEプロジェクト. http://www.jspm-peace.jp/, (閲覧 : 2017-07-30)

5) 日本緩和医療学会. ELNEC-J. https://www.jspm.ne.jp/elnec/elnec_about.html, (閲覧 : 2017-07-30)

6) 日本緩和医療薬学会. 薬剤師教育プログラムPEOPLE. https://jpps-education.jimdo.com/, (閲覧 : 2017-07-30)

7) 日本緩和医療学会. CLIC-T. https://www.jspm.ne.jp/clic/161106clic.html, (閲覧 : 2017-07-30)

8) 宮下光令. 緩和ケア臨床・研究・教育ツール (palliative care clinical, research and education tools) http://plaza.umin.ac.jp/~pcpkg/, (閲覧 : 2017-07-30)

9) 日本緩和医療学会. 関連学会・研究会・関連団体リンク https://www.jspm.ne.jp/, (閲覧 : 2017-07-23)

10) World Health Organization. Cancer Control. Knowledge into Action WHO Guide for Effective Programmes Palliative Care. Genova : WHO press ; 2007. pp.29-31.

11) 平原佐斗司. 緩和ケアにおける動向. 津田徹, 他 (編). 非がん性呼吸器疾患の緩和ケア : 全ての人にエンドオブライフケアの光を第1版. 東京 : 南山堂 ; 2017, pp.1-6.

P.398 掲載の参考文献

1) 日本緩和医療学会緩和医療ガイドライン作成委員会 (編). 終末期がん患者の輸液療法に関するガイドライン 2013年版. 東京 : 金原出版 ; 2013. pp.2-3.

2) 日本緩和医療学会緩和医療ガイドライン作成委員会 (編). 終末期がん患者の輸液療法に関するガイドライン 2013年版. 2013. https://www.jspm.ne.jp/guidelines/glhyd/2013/pdf/glhyd2013.pdf, (閲覧 : 2017-07-30)

3) 宮下光令. 緩和ケア臨床・研究・教育ツール (palliative care clinical, research and education tools). 2004. http://plaza.umin.ac.jp/~pcpkg/, (閲覧 : 2017-07-30)

4) 日本緩和医療学会緩和医療ガイドライン作成委員会 (編). 終末期がん患者の輸液療法に関するガイドライン 2013年版. 東京 : 金原出版 ; 2013. pp.66-145.

5) 小田切拓也, 他. 臨死期のケア. 日本緩和医療学会 (編). 専門家をめざす人のための緩和医療学第1版. 東京 : 南江堂 ; 2017. p.259-67.

6) 日本緩和医療学会緩和医療ガイドライン作成委員会 (編). 終末期がん患者の輸液療法に関するガイドライン 2013年版. 東京 : 金原出版 ; 2013. pp.41-3.

P.399 掲載の参考文献

1) 厚生労働省. 人生の最終段階における医療の決定プロセスに関するガイドライン. 平成19年5月 (改訂平成27年3月). http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/saisyu_iryou/index.html, (閲覧 : 2017-07-30)

2) 一般社団法人日本病院会. https://www.hospital.or.jp/index.html, (閲覧 : 2017-07-30)

3) 一般社団法人日本病院会倫理委員会. 日病文書配信. 「尊厳死」-人のやすらかな自然な死についての考察-. 2015. https://www.hospital.or.jp/pdf/06_20150424_01.pdf, (閲覧 : 2017-07-30)

4) 桂秀樹. 慢性閉塞性肺疾患の終末期医療と緩和ケアの意義. 日本臨床. 2003 ; 61 : 2212-9.

5) 有田健一, 他. 過去20年間における肺線維症・間質性肺炎終末期の緩和医療に関する検討. 日胸臨. 2010 ; 69 : 353-61.

6) 有田健一, 他. 在宅酸素療法を施行したCOPD (肺気腫型) における終末期の病態と緩和医療に関する検討. 日胸臨. 2009 ; 68 : 856-66.

各論

P.403 掲載の参考文献

1) McIsaac WJ, et al. The validity of a sore throat score in family practice. CMAJ. 2000 ; 163 : 811-5.

P.405 掲載の参考文献

1) Wenzel RP, et al. Clinical practice. Acute bronchitis. N Engl J Med. 2006 ; 355 : 2125-30.

P.408 掲載の参考文献

1) Ryu JH, et al. Bronchiolar disorders. Am J Respir Crit Care Med. 2003 ; 168 : 1277-92.

2) Ryu K, et al. Etiology and Outcome of Diffuse Acute Infectious Bronchiolitis in Adults. Ann Am Thorac Soc. 2015 ; 12 : 1781-7.

3) Mansbach JM, et al. Prospective multicenter study of the viral etiology of bronchiolitis in the emergency department. Acad Emerg Med. 2008 ; 15 : 111-8.

4) Midulla F, et al. Respiratory syncytial virus, human bocavirus and rhinovirus bronchiolitis in infants. Arch Dis Child. 2010 ; 95 : 35-41.

5) Kristoffersen AW, et al. Coronavirus causes lower respiratory tract infections less frequently than RSV in hospitalized Norwegian children. Pediatr Infect Dis J. 2011 ; 30 : 279-83.

6) Kapoor A, et al. Human bocaviruses are highly diverse, dispersed, recombination prone, and prevalent in enteric infections. J Infect Dis. 2010 ; 201 : 1633-43.

7) Nikki P, et al. Severe bronchiolitis probably caused by varicella-zoster virus. Crit Care Med. 1982 ; 10 : 344-6.

8) Heininger U, et al. Clinical findings in Bordetella pertussis infections : results of a prospective multicenter surveillance study. Pediatrics. 1997 ; 100 : E10.

9) Schuetz P, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections : the ProHOSP randomized controlled trial. JAMA. 2009 ; 302 : 1059-66.

P.414 掲載の参考文献

1) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会 (編). 成人肺炎診療ガイドライン 2017. 東京 : 日本呼吸器学会 ; 2017.

2) Maruyama T, et al. A new strategy for healthcare-associated pneumonia : a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis. 2013 ; 57 ; 1373-83.

3) Kawanami T, et al. Clinical impact of methicillin-resistant staphylococcus aureus on bacterial pneumonia : cultivation and 16S ribosomal RNA gene analysis of bronchoalveolar lavage fluid. BMC Infect Dis. 2016 ; 16 : 155.

4) Self WH, et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis. 2017 ; 65 : 183-90.

5) Suzuki M, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older : a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017 ; 17 : 313-21.

P.417 掲載の参考文献

1) Takayanagi N, et al. Etiology and outcome of community-acquired lung abscess. Respiration. 2010 ; 80 : 98-105.

2) Herth F, et al. Endoscopic drainage of lung abscesses : technique and outcome. Chest. 2005 ; 127 : 1378-81.

3) Bartlett JG. Lung abscess and necrotizing pneumonia. In : Gorbach SL, et al, eds. Infectious Diseses. Philadelphia : W. B. Saunders ; 1992.

4) Hirshberg B, et al. Factors predicting mortality of patients with lung abscess. Chest. 1999 ; 115 : 746-50.

P.422 掲載の参考文献

1) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会 (編). 成人肺炎診療ガイドライン. 2017.

2) Teramoto S, et al. Simple two-step swallowing provocation test for elderly patients with aspiration pneumonia. Lancet. 1999 ; 353 : 1243.

3) El-Solh AA, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med. 2003 ; 167 : 1650-4.

4) Bartlett JG, et al. The bacteriology of aspiration pneumonia. Am J Med. 1974 ; 56 : 202-7.

5) Ohkubo T, et al. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med. 2004 ; 169 : 1041-5.

6) Shinohara Y, et al. Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. Cerebrovasc Dis. 2006 ; 22 : 57-60.

P.424 掲載の参考文献

1) Baron SE, et al. Radiological and clinical findings in acute and chronic exogenous lipoid pneumonia. J Thorac Imaging. 2003 ; 18 : 217-24.

2) Gondouin A, et al. Exogenous lipid pneumonia : a retrospective multicentre study of 44 cases in France. Eur Respir J. 1996 ; 9 : 1463-9.

3) Betancourt SL, et al. Lipoid pneumonia : spectrum of clinical and radiologic manifestations. AJR Am J Roentgenol. 2010 ; 194 : 103-9.

4) Talwar A, et al. False-positive PET scan in a patient with lipoid pneumonia simulating lung cancer. Clin Nucl Med. 2004 ; 29 : 426-8.

5) Chang HY, et al. Successful treatment of diffuse lipoid pneumonitis with whole lung lavage. Thorax. 1993 ; 48 : 947-8.

6) Lococo F, et al. Idiopathic lipoid pneumonia successfully treated with prednisolone. Heart Lung. 2012 ; 41 : 184-7.

P.427 掲載の参考文献

1) Ito I, et al. Culturally verified Mycoplasma pneumoniae pneumonia in Japan : a long-term observation from 1979-99. Epidemiol Infect. 2001 ; 127 : 365-7.

2) 伊藤功朗. 小野寺昭一 (編). マイコプラズマ. 感染症内科学 (医学スーパーラーニングシリーズ). 東京 : 丸善出版 ; 2013.

3) 伊藤功朗, 他. Chlamydia pneumoniae肺炎, オウム病, マイコプラズマ肺炎の臨床的比較. 日本呼吸器学会雑誌. 2001 ; 39 : 172-7.

4) 伊藤功朗, 他. Chlamydia pneumoniae肺炎, オウム病, マイコプラズマ肺炎の胸部X線所見の比較検討. 感染症学雑誌. 2001 ; 74 : 954-60.

5) Ito I, et al. Differentiation of bacterial and non-bacterial community-acquired pneumonia by thin-section computed tomography. Eur J Radiol. 2009 ; 72 : 388-95.

P.431 掲載の参考文献

1) 伊藤功朗. 小野寺昭一 (編). クラミジア. 感染症内科学 (医学スーパーラーニングシリーズ). 東京 : 丸善出版 ; 2013.

2) 伊藤功朗, 他. Chlamydia pneumoniae肺炎, オウム病, マイコプラズマ肺炎の臨床的比較. 日本呼吸器学会雑誌. 2001 : 39 ; 172-7.

3) 伊藤功朗, 他. Chlamydia pneumoniae肺炎, オウム病, マイコプラズマ肺炎の胸部X 線所見の比較検討. 感染症学雑誌. 2000 ; 74 : 954-60.

4) 岸本寿男. Chlamydia pneumoniae感染症の基礎と臨床診断-血清学的診断. 化学療法の領域. 1996 ; 12 : 2250-6.

P.434 掲載の参考文献

1) 村上日奈子. 尿中レジオネラ抗原検査. モダンメディア. 2004 ; 50 : 86-91.

2) Sopena N, et al. Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. Chest. 1998 ; 113 : 1195-200.

3) Ito I, et al. Hot spring bath and Legionella pneumonia : an association confirmed by genomic identification. Intern Med. 2002 ; 41 : 859-63.

P.437 掲載の参考文献

1) 国立感染症研究所感染症疫学センター. インフルエンザウイルス分離・検出速報. https://www.niid.go.jp/niid/ja/diseases/a/flu.html

2) Gadsby NJ, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis. 2016 ; 62 : 817-23.

3) Agarwal PP, et al. Chest radiographic and CT findings in novel swine-origin influenza A (H1N1) virus (S-OIV) infection. Am J Roentgenol. 2009 ; 193 : 1488-93.

4) Muthuri SG, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection : a meta-analysis of individual participant data. Lancet Respir Med. 2014 ; 2 : 395-404.

5) Masclans JR, et al. Early non-invasive ventilation treatment for severe influenza pneumonia. Clin Microbiol Infect. 2013 ; 19 : 249-56.

6) Han K, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis. 2011 ; 53 : 326-33.

7) Iuliano AD, et al. Increase in Human Infections with Avian Influenza A (H7N9) Virus During the Fifth Epidemic-China, October 2016-February 2017. MMWR Morb Mortal Wkly Rep. 2017 ; 66 : 254-55.

P.440 掲載の参考文献

1) 矢田純一. 医系免疫学第14版. 東京 : 中外医学社 ; 2016.

2) Freifeld AG, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011 ; 52 : e56-93.

3) Meersseman W, et al. Galactomannan in bronchoalveolar lavage fluid : a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008 ; 177 : 27-34.

P.442 掲載の参考文献

1) 御手洗聡. 細菌検査. 日本結核病学会 (編). 非結核性抗酸菌症診療マニュアル. 東京 : 医学書院 ; 2015. pp.16-33.

2) 菊地利明. 日本と世界の疫学の動向について. 日本結核病学会 (編). 非結核性抗酸菌症診療マニュアル. 東京 : 医学書院 ; 2015. pp.2-14.

3) Namkoong H, et al. Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan. Emerg Infect Dis. 2016 ; 22 : 1116-7.

P.448 掲載の参考文献

1) 日本結核病学会教育委員会. 結核症の基礎知識 (改訂第4版). 結核. 2014 ; 89 : 521-45.

2) Nahid P, et al. Offical American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines : Treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016 ; 63 : e147-95.

3) 日本結核病学会治療委員会. 「結核医療の基準」の改訂-2018年. 結核. 2018 ; 93 : 61-8.

4) 日本結核病学会予防委員会・治療委員会. 潜在性結核感染症治療指針. 結核. 2013 ; 88 : 497-512.

5) Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR. 2005 ; 54 (RR-17) : 1-141.

P.453 掲載の参考文献

1) Griffith DE, et al. An official ATS/IDSA statement : diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 ; 175 : 367-416.

2) Boyle DP, et al. Comparison of Clinical Features, Virulence, and Relapse among Mycobacterium avium Complex Species. Am J Respir Crit Care Med. 2015 ; 191 : 1310-7.

3) Minomo S, et al. A unique case of hot tub lung worsening during the winter. Intern Med. 2015 ; 54 : 491-5.

4) Chou CH, et al. Clinical features and outcomes of disseminated infections caused by non-tuberculous mycobacteria in a university hospital in Taiwan, 2004-2008. Scand J Infect Dis. 2011 ; 43 : 8-14.

5) Kitada S, et al. Validation of a commercial serodiagnostic kit for diagnosing pulmonary Mycobacterium avium complex disease. Int J Tuberc Lung Dis. 2015 ; 19 : 97-103.

6) Kobashi Y, et al. Serological assay by use of glycopeptidolipid core antigen for Mycobacterium avium complex. Scand J Infect Dis. 2013 ; 45 : 241-9.

7) Tanaka E, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999 ; 160 : 866-72.

8) Morimoto K, et al. Macrolide-Resistant Mycobacterium avium Complex Lung Disease : Analysis of 102 Consecutive Cases. Ann Am Thorac Soc. 2016 ; 13 : 1904-11.

9) Bermudez LE, et al. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. J Infect Dis. 2003 ; 187 : 1977-80.

10) Fujita M, et al. [Measurement of sitafloxacin MIC for Mycobacterium avium complex and application for treatment of pulmonary nontuberculous mycobacteriosis]. Jpn J Antibiot. 2014 ; 67 : 395-400.

11) Falkinham JO 3rd. Reducing human exposure to Mycobacterium avium. Ann Am Thorac Soc. 2013 ; 10 : 378-82.

12) Griffith DE, et al. An Official ATS/IDSA Statement : Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am J Respir Crit Care Med. 2007 ; 175 : 367-416.

13) Jarand J, et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011 ; 52 : 565-71.

14) Koh WJ, et al. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. Clin Infect Dis. 2017 ; 64 : 309-16.

15) Zoumot Z, et al. Mycobacterium avium complex infection in non-cystic fibrosis bronchiectasis. Respirology. 2014 ; 19 : 714-22.

16) Kobashi Y, et al. Chronic necrotizing pulmonary aspergillosis as a complication of pulmonary Mycobacterium avium complex disease. Respirology. 2006 ; 11 : 809-13.

17) Naito M, et al. Internal Medicine. in press

18) Koh WJ, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011 ; 183 : 405-10.

19) Harada T, et al. Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol. 2012 ; 50 : 3556-61.

P.456 掲載の参考文献

1) Bennett JE, et al. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 8th ed. London : Churchill Livingstone ; 2015.

P.461 掲載の参考文献

1) 深在性真菌症のガイドライン作成委員会 (編). 深在性真菌症の診断・治療ガイドライン 2014. 東京 : 協和企画 ; 2014.

2) Mandell GA, et al. Principles and Practice of Infectious Diseases 7th ed. London : Churchill Livingstone ; 2009.

P.464 掲載の参考文献

1) Okamoto K, et al. Cryptococcus gattii genotype VGIIa infection in man, Japan, 2007. Emerg Infect Dis. 2010 ; 16 : 1155-7.

2) 深在性真菌症のガイドライン作成委員会 (編). 深在性真菌症の診断・治療ガイドライン 2014. 東京 : 協和企画 ; 2014.

3) Philip S, editor. Spencer's Pathology of the Lung. 5th ed. New York : McGrawHill ; 1950.

P.468 掲載の参考文献

1) Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents.

P.473 掲載の参考文献

1) Suzuki Y, et al. Epidemiology of visceral mycoses in autopsy cases in Japan : the data from 1989 to 2009 in the Annual of Pathological Autopsy Cases in Japan. Med Mycol. 2013 ; 51 : 522-6.

2) 深在性真菌症のガイドライン作成委員会 (編). 深在性真菌症の診断・治療ガイドライン 2014. 東京 : 協和企画 ; 2014.

P.475 掲載の参考文献

1) 日本造血細胞移植学会. 造血細胞移植ガイドラインサイトメガロウイルス感染症第2版. 2011.

2) Arai T, et al. Cytomegalovirus infection during immunosuppressive therapy for diffuse parenchymal lung disease. Respirology. 2013 ; 18 : 117-24.

P.478 掲載の参考文献

1) Akao N, et al. Toxocariasis in Japan. Parasitol Int. 2007 ; 56 : 87-93.

2) 斎藤厚. 糞線虫. 臨床と微生物. 1990 ; 17 : 607-11.

3) Boggild AK, et al. Tropical pulmonary eosinophilia : a case series in a setting of nonendemicity. Clin Infect Dis. 2004 ; 39 : 1123-8.

4) 熱帯病治療薬研究班. 寄生虫症薬物治療の手引き 2017 改訂第9.2版. 2017.

P.481 掲載の参考文献

1) American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 ; 171 : 388-416.

2) 日本呼吸器学会医療・介護関連肺炎診療 (NHCAP) ガイドライン作成委員会 (編). 医療・介護関連肺炎 (NHCAP) 診療ガイドライン. 2011.

3) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会 (編). 成人肺炎診療ガイドライン 2017. 2017.

4) Ito I, et al. Isolation of drug-resistant pathogens does not always require use of broad-spectrum antibiotics in pneumonia. Am J Respir Crit Care Med. 2014 ; 189 : 756-7.

P.484 掲載の参考文献

1) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会 (編). 成人院内肺炎診療ガイドライン. 2008.

2) 日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会 (編). 成人肺炎診療ガイドライン 2017. 2017.

3) Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med. 2001 ; 29 (4 Suppl) : N64-8.

4) Chastre J, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults : a randomized trial. JAMA. 2003 ; 290 : 2588-98.

P.488 掲載の参考文献

1) 日本結核病学会非結核性抗酸菌症対策委員会. 肺非結核性抗酸菌症に対する外科治療の指針. 結核. 2008 ; 83 : 527-8.

P.498 掲載の参考文献

1) 日本呼吸器学会COPDガイドライン第5版作成委員会 (編). COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン 2018 (第5版). 東京 : メディカルレビュー社 ; 2018.

2) Vogelmeier CF, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017 ; 195 : 557-82.

3) Tokuda Y, et al. Physical diagnosis of chronic obstructive pulmonary disease. Intern Med. 2007 ; 46 : 1885-91.

4) ウエスト呼吸生理学入門 : 疾患肺編第2版. 東京 ; メディカル・サイエンス・インターナショナル ; 2018.

5) 佐藤晋. COPD・肺気腫におけるメカノバイオロジー. 呼吸臨床. 2017 ; 1 : e00018.

6) Tanabe N, et al. Computed tomography assessment of pharmacological lung volume reduction induced by bronchodilators in COPD. COPD. 2012 ; 9 : 401-8.

7) 日本呼吸器学会喘息とCOPDのオーバーラップ (Asthma and COPD Overlap : ACO) 診断と治療の手引き2018作成委員会 (編). 喘息とCOPDのオーバーラップ (Asthma and COPD Overlap : ACO) 診断と治療の手引き 2018. 東京 : メディカルレビュー社 ; 2017.

8) 日本呼吸ケア・リハビリテーション学会, 日本呼吸器学会, 日本リハビリテーション医学会, 日本理学療法士協会 (編). 呼吸リハビリテーションマニュアル-運動療法-第2版. 東京 ; 照林社 : 2012.

9) Lange P, et al. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med. 2015 ; 373 : 111-22.

P.501 掲載の参考文献

1) Cottin V, et al. Combined pulmonary fibrosis and emphysema : a distinct underrecognised entity. Eur Respir J. 2005 ; 26 : 586-93.

2) Cottin V, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010 ; 35 : 105-11.

3) Wells AU, et al. Lone cryptogenic fibrosing alveolitis : a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med. 1997 ; 155 : 1367-75.

4) Jacob J, et al. Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. Eur Respir J. 2017 ; 50 : 1700379.

5) Ryerson CJ, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013 ; 144 : 234-40.

P.504 掲載の参考文献

1) McShane PJ, et al. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013 ; 188 : 647-56.

P.508 掲載の参考文献

1) 難病情報センター. 閉塞性細気管支炎 (指定難病 228). http://www.nanbyou.or.jp/entry/4721

2) 日本呼吸器学会 (監). 難治性びまん性肺疾患診療の手引き. 東京 : 南江堂 ; 2017.

3) Miller WT Jr, et al. Expiratory air trapping on thoracic computed tomography. A diagnostic subclassification. Ann Am Thorac Soc. 2014 ; 11 : 874-81.

4) Estenne M, et al. Bronchiolitis obliterans syndrome 2001 : an update of the diagnostic criteria. J Heart Lung Transplant. 2002 ; 21 : 297-310.

5) 厚生労働科学研究費補助金難治性疾患政策研究事業びまん性肺疾患に関する調査研究班. びまん性肺疾患に関する調査研究平成23年度研究報告書.

6) 長谷川好規. 閉塞性細気管支炎の現状. 日内会誌. 2008 ; 97 : 1895-9.

P.511 掲載の参考文献

1) Homma H, et al. Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest. 1983 ; 83 : 63-9.

2) Kudoh S, et al. Diffuse panbronchiolitis. Clin Chest Med. 2012 ; 33 : 297-305.

3) Kono C, et al. Historical changes in epidemiology of diffuse panbronchiolitis. Sarcoidosis Vasc Diffuse Lung Dis. 2012 ; 29 : 19-25.

4) 中田紘一郎. DPBの診断指針改訂と重症度分類策定. 厚労省特定疾患呼吸器系疾患調査研究班びまん性肺疾患分科会. 平成10年度研究報告書. 1999. pp. 109-11.

P.514 掲載の参考文献

1) 日本気胸・嚢胞性肺疾患学会 (編). 気胸・嚢胞性肺疾患規約・用語・ガイドライン 2009年版. 東京 : 金原出版 : 2009.

2) Webb WR, et al eds. High-Resolution CT of the Lung, 5th ed. Alphen aan den Rijn : Wolters Kluwer ; 2015.

3) Dal Sasso AA, et al. Birt-Hogg-Dube syndrome. State-of-the-art review with emphasis on pulmonary involvement. Respir Med. 2015 ; 109 : 289-96.

4) 飛野和則, 他. Birt-Hogg-Dube症候群. 呼吸. 2013 ; 32 : 164-72.

5) Menko FH, et al. Birt-Hogg-Dube syndrome : diagnosis and management. Lancet Oncol. 2009 ; 10 : 1199-206.

P.518 掲載の参考文献

1) 日本医師会 (編). 胸部X線写真のABC. 東京 : 医学書院 ; 1990.

2) 郡義明. 胸部X線診断に自信がつく本第2版. 埼玉 : カイ書林 ; 2014.

3) Stathopoulos GT, et al. Rounded atelectasis of the lung. Respir Med. 2005 ; 99 : 615-23.

P.524 掲載の参考文献

1) 日本アレルギー学会喘息ガイドライン専門部会監修. 喘息予防・管理ガイドライン 2018. 東京 : 協和企画 ; 2018.

2) 井上博雅, 他 (編). 気管支喘息. 東京 : 中山書店 ; 2017.

3) ten Brinke A, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J. 2005 ; 26 : 812-8.

4) Boulet LP, et al. Influence of comorbid conditions on asthma. Eur Respir J. 2009 ; 33 : 897-906.

5) 日本呼吸器学会難治性喘息診断と治療の手引き2019作成委員会 (編). 難治性喘息診断と治療の手引き 2019. 東京 : メディカルレビュー社 ; 2019.

P.527 掲載の参考文献

1) Niimi A, et al. Eosinophilic airway disorders associated with chronic cough. Pulm Pharmacol Ther. 2009 ; 22 :114-20.

2) 日本呼吸器学会咳嗽と喀痰の診療ガイドライン2019作成委員会 (編). 咳嗽と喀痰の診療ガイドライン 2019. 東京 : メディカルレビュー社 ; 2019.

3) 新実彰男. 慢性咳嗽の病態, 鑑別診断と治療-咳喘息を中心に-. 日本内科学会雑誌. 2016 ; 105 : 1565-77.

4) Asano T, et al. Diagnostic utility of fractional exhaled nitric oxide in prolonged and chronic cough according to atopic status. Allergol Int. 2017 ; 66 : 344-50.

5) Takemura M, et al. Clinical, physiological and anti-inflammatory effect of montelukast in patients with cough variant asthma. Respiration. 2012 ; 83 : 308-15.

6) Fukumitsu K, et al. Tiotropium Attenuates Refractory Cough and Capsaicin Cough Reflex Sensitivity in Patients with Asthma. J Allergy Clin Immunol Pract. 2018 ; 6 : 1613-20. e2.

P.532 掲載の参考文献

1) Allen JN, et al. Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med. 1989 ; 321 : 569-74.

2) Badesch DB, et al. Acute eosinophilic pneumonia : a hypersensitivity phenomenon? Am Rev Respir Dis. 1989 ; 139 : 249-52.

3) Janz DR, et al. Acute eosinophilic pneumonia : A case report and review of the literature. Crit Care Med. 2009 ; 37 : 1470-4.

4) Uchiyama H, et al. Alterations in smoking habits are associated with acute eosinophilic pneumonia. Chest. 2008 ; 133 : 1174-80.

5) Solomon J, et al. Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia. Semin Respir Crit Care Med. 2006 ; 27 : 192-7.

6) Daimon T, et al. Acute eosinophilic pneumonia : Thin-section CT findings in 29 patients. Eur J Radiol. 2008 ; 65 : 462-7.

7) Cottin V, et al. Eosinophilic pneumonias. Allergy. 2005 ; 60 : 841-57.

8) Mochimaru H, et al. Clinicopathological differences between acute and chronic eosinophilic pneumonia. The Journal of the Japanese Respiratory Society. 2007 ; 45 : 223-32.

9) Carrington CB, et al. Chronic eosinophilic pneumonia. N Engl J Med. 1969 ; 280 : 787-98.

10) Jederlinic PJ, et al. Chronic eosinophilic pneumonia. A report of 19 cases and a review of the literature. Medicine (Baltimore). 1988 ; 67 : 154-62.

11) Mochizuki Y, et al. Chronic eosinophilic pneumonia-a follow-up study of 12 cases-. The Journal of the Japanese Respiratory Society. 2002 ; 40 : 851-5.

12) Marchand E, et al. Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore). 1998 ; 77 : 299-312.

P.536 掲載の参考文献

1) Greenberger PA, et al. Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma. J Allergy Clin Immunol. 1988 ; 81 : 646-50.

2) Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002 ; 110 : 685-92.

3) Agarwal R, et al. Allergic bronchopulmonary aspergillosis : Review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013 ; 43 : 850-73.

4) Oguma T, et al. Allergic bronchopulmonary aspergillosis in Japan : A nationwide survey. Allergol Int. 2018 ; 67 : 79-84.

5) Chowdhary A, et al. Allergic bronchopulmonary mycosis due to fungi other than Aspergillus : a global overview. Crit Rev Microbiol. 2014 ; 40 : 30-48.

P.539 掲載の参考文献

1) 厚生労働科学研究費補助金難治性疾患政策研究事業. ANCA関連血管炎診療ガイドライン 2017. 東京 : 診断と治療社 ; 2017.

2) Guillevin L, et al. French Vasculitis Study Group (FVSG). The Five-Factor Score revisited : assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011 ; 90 : 19-27.

3) Tsurikisawa N, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2004 ; 92 : 80-7.

4) Wechsler ME, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017 ; 376 : 1921-32.

P.544 掲載の参考文献

1) Selman M, et al. Hypersensitivity Pneumonitis : Insights in Diagnosis and Pathobiology. Am J Respir Crit Care Med. 2012 ; 186 : 314-24.

2) Okamoto T, et al. Nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan. Respir Investig. 2013 ; 51 : 191-9.

3) Morisset J, et al. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis : An International Modified Delphi Survey. Am J Respir Crit Care Med. 2018 ; 197 : 1036-44.

4) Patel AM, et al. Hypersensitivity pneumonitis : Current concepts and future questions. J Allergy Clin Immunol. 2001 ; 108 : 661-70.

5) 稲瀬直彦, 他. 鳥関連過敏性肺炎の診断における鳥特異抗体. 日本呼吸器学会雑誌. 2011 ; 49 : 717-22.

P.550 掲載の参考文献

1) American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018 ; 198 : e44-e68.

2) Travis WD, et al. ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 ; 188 : 733-48.

3) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会 (編). 特発性間質性肺炎診断と治療の手引き改訂第3版. 東京 : 南江堂 ; 2016.

4) Natsuizaka M, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014 ; 190 : 773-9.

5) Bando M, et al. A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan. Respir Investig. 2015 ; 53 : 51-9.

P.554 掲載の参考文献

1) Katzenstein AL, et al. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol. 1994 ; 18 : 136-47.

2) American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002 ; 165 : 277-304.

3) Travis WD, et al. Idiopathic nonspecific interstitial pneumonia : report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008 ; 177 : 1338-47.

4) Travis WD, et al. An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 ; 188 : 733-48.

5) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会 (編). 特発性間質性肺炎診断と治療の手引き改訂第3版. 東京 : 南江堂 ; 2016.

P.557 掲載の参考文献

1) Travis WD, et al. An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 ; 188 : 733-48.

2) American Thoracic Society ; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002 ; 165 : 277-304.

3) Epler GR, et al. Bronchiolitis obliterans organizing pneumonia. N Engl J Med. 1985 ; 312 : 152-8.

4) Izumi T, et al. Bronchiolitis obliterans organizing pneumonia. Clinical features and differential diagnosis. Chest. 1992 ; 102 : 715-9.

5) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会 (編). 特発性間質性肺炎診断と治療の手引き改訂第2版. 東京 : 南江堂 ; 2011. pp.88-92.

6) Beardsley B, et al. Fibrosing organising pneumonia. J Clin Pathol. 2013 ; 66 : 875-81.

P.560 掲載の参考文献

1) Godbert B, et al. Desquamative interstitial pneumonia : an analytic review with an emphasis on aetiology. Eur Respir Rev. 2013 ; 22 : 117-23.

2) Vassallo R, et al. Tobacco smoke-related diffuse lung diseases. Semin Respir Crit Care Med. 2008 ; 29 : 643-50.

3) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会 (編). 特発性間質性肺炎診断と治療の手引き改訂第3版. 東京 : 南江堂 ; 2016.

4) Ryu JH, et al. Desquamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease. Chest. 2005 ; 127 : 178-84.

5) Verleden GM, et al. Possible recurrence of desquamative interstitial pneumonitis in a single lung transplant recipient. Eur Respir J. 1998 ; 11 : 971-4.

P.562 掲載の参考文献

1) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会 (編). 特発性間質性肺炎診断と治療の手引き改訂第3版. 東京 : 南江堂 ; 2016.

2) Vassallo R, et al. Tobacco smoke-related diffuse lung diseases. Semin Respir Crit Care Med. 2008 ; 29 : 643-50.

3) Travis WD, et al. ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 ; 188 : 733-48.

4) Wells AU, et al. Challenges in pulmonary fibrosis. 4 : smoking-induced diffuse interstitial lung diseases. Thorax. 2007 ; 62 : 904-10.

P.563 掲載の参考文献

1) Liebow AA, et al. Diffuse pulmonary lymphoreticular infiltrations associated with dysproteinemia. Med Clin North Am. 1973 ; 57 : 809-43.

2) American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002 ; 165 : 277-304.

3) Travis WD, et al. An Official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 ; 188 : 733-48.

4) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会 (編). 特発性間質性肺炎診断と治療の手引き改訂第3版. 東京 : 南江堂 ; 2016. pp.1-156.

P.567 掲載の参考文献

1) Katzenstein AL, et al. Acute interstitial pneumonia. A clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol. 1986 ; 10 : 256-67.

2) Hamman BL, et al. Acute diffuse interstitial fibrosis of the lungs. Bull Johns Hopkins Hosp. 1944 ; 74 : 177-212.

3) Askin FB. Back to the future : the Hamman-Rich syndrome and acute interstitial pneumonia. Mayo Clin Proc. 1990 ; 65 : 1624-6.

4) Olson J, et al. Hamman-Rich syndrome revisited. Mayo Clin Proc. 1990 ; 65 : 1538-48.

5) Quefatieh A, et al. Low hospital mortality in patients with acute interstitial pneumonia. Chest. 2003 ; 124 : 554-9.

6) Suh GY, et al. Early intervention can improve clinical outcome of acute interstitial pneumonia. Chest. 2006 ; 129 : 753-61.

7) Nagai S, et al. Classification and recent advances in idiopathic interstitial pneumonia. Curr Opin Pulm Med. 1998 ; 4 : 256-60.

8) Johkoh T, et al. Acute interstitial pneumonia : thin-section CT findings in 36 patients. Radiology. 1999 ; 211 : 859-63.

9) Ichikado K, et al. Acute interstitial pneumonia : comparison of high-resolution computed tomography findings between survivors and nonsurvivors. Am J Respir Crit Care Med. 2002 ; 165 : 1551-6.

P.570 掲載の参考文献

1) 網谷良一, 他. 特発性上葉限局型肺線維症. 呼吸. 1992 ; 11 : 693 -9.

2) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会 (編). 特発性間質性肺炎診断と治療の手引き改訂第3版. 東京 : 南江堂 ; 2016.

3) Watanabe K. Pleuroparenchymal Fibroelastosis : Its Clinical Characteristics. Curr Respir Med Rev. 2013 ; 229-37.

4) Bonifazi M, et al. Idiopathic Pleuroparenchymal Fibroelastosis. Curr Pulmonol Rep. 2017 ; 6 : 9-15.

5) Nakatani T, et al. Pleuroparenchymal fibroelastosis from a consecutive database : a rare disease entity? Eur Respir J. 2015 ; 45 : 1183-6.

6) Reddy TL, et al. Pleuroparenchymal fibroelastosis : a spectrum of histopathological and imaging phenotypes. Eur Respir J. 2012 ; 40 : 377-85.

P.573 掲載の参考文献

1) American Thoracic Society ; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 202 ; 165 : 277-304. Erratum in : Am J Respir Crit Care Med. 2002 ; 166 : 426.

2) Travis WD, et al. An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 ; 188 : 733-48.

3) Skolnik K, et al. Unclassifiable interstitial lung disease : A review. Respirology. 2016 ; 21 : 51-6.

4) Ryerson CJ, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013 ; 42 : 750-7.

5) Kondoh Y, et al. Clinical spectrum and prognostic factors of possible UIP pattern on high-resolution CT in patients who underwent surgical lung biopsy. PLoS One. 2018 ; 13 : e0193608.

P.578 掲載の参考文献

1) Fischer A, et al. An official European Respiratory Society/American Thoracic Society research statement : interstitial pneumonia with autoimmune features. Eur Respir J. 2015 ; 46 : 976-87.

2) Tashkin DP, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 ; 354 : 2655-66.

3) Tashkin DP, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II) : a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 ; 4 : 708-19.

4) Suda T, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med. 2009 ; 103 : 846-53.

5) Wallace B, et al. Management of connective tissue diseases associated interstitial lung disease : a review of the published literature. Curr Opin Rheumatol. 2016 ; 28 : 236-45.

6) Park JH, et al. Prognosis of fibrotic interstitial pneumonia : idiopathic versus collagen vascular disease-related subtypes.

P.583 掲載の参考文献

1) Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999 ; 160 : 736-55.

2) Morimoto T, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008 ; 31 : 372-9.

3) 杉山幸比古 (監). 呼吸器科医のためのサルコイドーシス診療ガイド. 東京 : 南江堂 ; 2016. pp.139-43.

4) 四十坊典晴, 他. わが国におけるサルコイドーシスの診断基準と重症度分類. 日サ会誌. 2015 ; 35 : 3-8.

5) サルコイドーシス診断基準改定委員会. サルコイドーシスの診断基準と診断の手引き-2015.

6) サルコイドーシス治療ガイドライン策定委員会. サルコイドーシス治療に関する見解-2003. 日サ会誌. 2003 ; 23 : 105-14.

P.587 掲載の参考文献

1) Lally L, et al. Pulmonary vasculitis. Rheum Dis Clin North Am. 2015 ; 41 : 315-31.

2) 尾崎承一, 他 (編). 厚生労働省難治性疾患克服研究事業難治性血管炎に関する調査研究班/進行性腎障害に関する調査研究班. ANCA関連血管炎の診療ガイドライン (2014年改訂版). 2014.

3) Katsumata Y, et al. Interstitial Lung Disease with ANCA-associated Vasculitis. Clin Med Insights Circ Respir Pulm Med. 2015 ; 9 (Suppl 1) : 51-6.

4) Homma S, et al. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology. 2004 ; 9 : 190-6.

5) Tanaka T, et al. Interstitial pneumonia associated with MPO-ANCA : clinicopathological features of nine patients. Respir Med. 2012 ; 106 : 1765-70.

6) Mukhtyar C, et al. European Vasculitis Study Group (EUVAS). Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis : a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008 ; 67 : 1004-10.

P.590 掲載の参考文献

1) Vassallo R, et al. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med. 2000 ; 342 : 1969-78.

2) Vassallo R, et al. Clinical outcomes of pulmonary Langerhans'- cell histiocytosis in adults. N Engl J Med. 2002 ; 346 : 484-90.

3) Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J. 2006 ; 27 : 1272-85.

4) Kim HJ, et al. Pulmonary Langerhans cell histiocytosis in adults : high-resolution CT-pathology comparisons and evolutional changes at CT. Eur Radiol. 2011 ; 21 : 1406-15.

5) Crausman RS, et al. Pulmonary histiocytosis X : pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med. 1996 ; 153 : 426-35.

P.594 掲載の参考文献

1) 厚生労働科学研究費補助金難治性疾患克服研究事業アミロイドーシスに関する調査研究班. アミロイドーシス診療ガイドライン 2010. 2010.

P.598 掲載の参考文献

1) Lazor R, et al. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. The Groupe d'Etudes et de Recherche sur les Maladles "Orphelines" Pulmonaires (GERM "O" P). Am J Respir Crit Care Med. 2000 ; 162 : 571-7.

2) Swerdlow SH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 ; 127 : 2375-90.

3) 日本血液学会. 造血器腫瘍診療ガイドライン (第1.2版). 2013.

4) Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Program. 2005 : 307-13.

5) Dunleavy K, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013 ; 368 : 1408-16.

P.600 掲載の参考文献

1) Doran HM, et al. Pathology of the lung in leukaemia and lymphoma : a study of 87 autopsies. Histopathology. 1991 ; 18 : 211-9.

2) Tanaka N, et al. CT findings of leukemic pulmonary infiltration with pathologic correlation. Eur Radiol. 2002 ; 12 : 166-74.

3) Kadota J, et al. Clinical Similarities and Differences Between Human T-Cell Lymphotropic Virus Type 1-Associated Bronchiolitis and Diffuse Panbronchiolitis. Chest. 2004 ; 125 : 1239-47.

P.602 掲載の参考文献

1) Grilo-Bensusan I, et al. Hepatopulmonary syndrome : What we know and what we would like to know. World J Gastroenterol. 2016 ; 22 : 5728-41.

2) Aldenkortt F, et al. Portopulmonary hypertension and hepatopulmonary syndrome. World J Gastroenterol. 2014 ; 20 : 8072-81.

3) Majewski S, et al. Pulmonary manifestations of inflammatory bowel disease. Arch Med Sci. 2015 ; 11 : 1179-88.

4) Ji XQ, et al. Pulmonary manifestations of inflammatory bowel disease. World J Gastroenterol. 2014 ; 20 : 13501-11.

5) 日本消化器病学会 (編). 胃食道逆流症 (GERD) 診療ガイドライン 2015 改訂第2版. 東京 : 南江堂 ; 2015.

6) Houghton LA, et al. Respiratory disease and the oesophagus : reflux, reflexes and microaspiration. Nat Rev Gastroenterol Hepatol. 2016 ; 13 : 445-60.

P.606 掲載の参考文献

1) Chi AK, et al. An update on pulmonary complications of hematopoietic stem cell transplantation. Chest. 2013 ; 144 : 1913-22.

2) Capizzi SA, et al. Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001 ; 27 : 1299-303.

3) Panoskaltsis-Mortari A, et al. An official American Thoracic Society research statement : noninfectious lung injury after hematopoietic stem cell transplantation : idiopathic pneumonia syndrome. Am J Respir Crit Care Med. 2011 ; 183 : 1262-79.

4) Fukuda T, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood. 2003 ; 102 : 2777-85.

5) Yanik GA, et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood. 2008 ; 112 : 3073-81.

6) Jagasia MH, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease : I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015 ; 21 : 389-401.e1.

7) Corris PA, et al. A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax. 2015 ; 70 : 442-50.

8) von der Thusen JH, et al. Pleuroparenchymal fibroelastosis in patients with pulmonary disease secondary to bone marrow transplantation. Mod Pathol. 2011 ; 24 : 1633-9.

9) Hirota T, et al. Pleuroparenchymal fibroelastosis as a manifestation of chronic lung rejection? Eur Respir J. 2013 ; 41 : 243-5.

10) Ofek E, et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis. Mod Pathol. 2013 ; 26 : 350-6.

P.611 掲載の参考文献

1) Yusen RD, et al. The Registry of the International Society for Heart and Lung Transplantation : Thirty-third Adult Lung and Heart-Lung Transplant Report-2016 ; Focus Theme : Primary Diagnostic Indications for Transplant. J Heart Lung Transplant. 2016 ; 35 : 1170-84.

2) Verleden GM, et al. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014 ; 33 : 127-33.

3) Estenne M, et al. Bronchiolitis obliterans syndrome 2001 : an update of the diagnostic criteria. J Heart Lung Transplant. 2002 ; 21 : 297-310.

4) Ohata K, et al. Cytomegalovirus Infection in Living-Donor and Cadaveric Lung Transplantations. Interact Cardiovasc Thorac Surg. 2017 ; 25 : 710-5.

5) Tanaka S, et al. Malignancies after living-donor and cadaveric lung transplantations in Japanese patients. Surg Today. 2016 ; 46 : 1415-9.

P.615 掲載の参考文献

1) 日本呼吸器学会薬剤性肺障害の診断・治療の手引き作成委員会 (編). 薬剤性肺障害の診断・治療の手引き. 東京 : メディカルレビュー社 ; 2012.

2) Camus P, et al. Interstitial lung disease induced by drugs and radiation. Respiration. 2004 ; 71 : 301-26.

3) Ohnishi H, et al. Circulating KL-6 levels in patients with drug-induced pneumonitis. Thorax. 2003 ; 58 : 872-5.

4) Niho S, et al. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs. Jpn J Clin Oncol. 2006 ; 36 : 269-73.

5) Hirata S, et al. Lymphocyte transformation test is not helpful for the diagnosis of methotrexate-induced pneumonitis in patients with rheumatoid arthritis. Clin Chim Acta. 2009 ; 407 : 25-9.

P.616 掲載の参考文献

1) Brooks SM, et al. Reactive airways dysfunction syndrome (RADS). Persistent asthma syndrome after high level irritant exposures. Chest. 1985 ; 88 : 376-84.

P.624 掲載の参考文献

1) WHO Air quality guidelines for particulate matter, ozone, nitrogen dioxide and sulfur dioxide Global update 2005 Summary of risk assessment. WHO2005-6.

2) Castaneda AR, et al. Fine particulate matter (PM 2.5) enhances allergic sensitization in BALB/c mice. J Toxicol Environ Health A. 2017 ; 80 : 197-207.

3) Falcon-Rodriguez CI, et al. Inhalation of concentrated PM 2.5 from Mexico City acts as an adjuvant in a guinea pig model of allergic asthma. Environ Pollut. 2017 ; 228 : 474-83.

4) Chakraborty S, et al. Nanoparticles increase human bronchial epithelial cell susceptibility to respiratory syncytial virus infection via nerve growth factor-induced autophagy. Physiol Rep. 2017 ; 5 : pii : 5/13/e13344.

5) Greenberg N, et al. Modeling long-term effects attributed to nitrogen dioxide (NO2) and sulfur dioxide (SO2) exposure on asthma morbidity in a nationwide cohort in Israel. J Toxicol Environ health A. 2017 ; 80 : 326-37.

6) Meldrum K, et al. Diesel exhaust particulate associated chemicals attenuate expression of CXCL10 in human primary bronchial epithelial cells. Toxicol in Vitro. 2017 ; 45 : 409-16.

7) Perret JL, et al. The dose-response assocaitetion between nitrogen dioxide exposure and serum interleukin-6 concentrations. Int J Mol Sci. 2017 ; 18 : pii : E1015.

8) Int Panis L, et al. Short-term air pollution exposure decreases lung function : a repeated measures study in healthy adults. Environ Health. 2017 ; 16 : 60. doi : 10.1186/s12940-017-0271-z.

9) Weichenthal S, et al. Long-term exposure to ambient ultrafine particles and respiratory disease incidence in Tronto, Canada : a cohort study. Environ Health. 2017 ; 16 : 64.

10) Burbank AJ, et al. Environmental determinants of allergy and asthma in early life. J Allergy Clin Immunol. 2017 ; 140 : 1-12.

11) Cai HL, et al. Surving with smog and smoke ; Precision interventions? Chest. 2017 ; 152 : 925-9.

12) Gold DR, et al. NIAID, NIEHS, NHLBI, and MCAN Workshop Report : The indoor environment and childhood asthma-implications for home environmental intervention in asthma prevention and management. J Allergy Clin Immunol. 2017 ; 140 : 933-49.

P.626 掲載の参考文献

1) Proudfoot AT, et al. Paraquat poisoning : significance of plasma-paraquat concentrations. Lancet. 1979 ; 2 : 330-2.

2) Wu WP, et al. Addition of immunosuppressive treatment to hemoperfusion is associated with improved survival after paraquat poisoning : a nationwide study. PLoS One. 2014 ; 9 : e87568.

P.629 掲載の参考文献

1) 冨岡洋海. 急性に発症する間質性肺炎 2) 特発性間質性肺炎 (IIPs) 以外. Hospitalist. 2015 ; 3 : 133-50.

2) Movsas B, et al. Pulmonary radiation injury. Chest. 1997 ; 111 : 1061-76.

3) Sekine I, et al. Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients. Radiother Oncol. 2006 ; 80 : 93-7.

4) 冨岡洋海. 放射線性肺炎. 今日の臨床サポート. 2017. http://clinicalsup.jp/jpoc/

5) Matsuno Y, et al. Simultaneous measurements of KL-6 and SP-D in patients undergoing thoracic radiotherapy. Med Oncol. 2006 ; 23 : 75-82.

6) Ogo E, et al. A survey of radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy in Japan. Int J Radiat Oncol Biol Phys. 2008 ; 71 : 123-31.

P.633 掲載の参考文献

1) 労災疾病等医学研究普及サイト. http://www.research.johas.go.jp/jinpai/11.html

2) Ozkan M, et al. FDG PET findings in a case with acute pulmonary silicosis. Ann Nucl Med. 2009 ; 23 : 883-6.

3) Cowie RL. The epidemiology of tuberculosis in gold miners with silicosis. Am J Respir Crit Care Med. 1994 ; 150 : 1460-2.

4) Ng TP, et al. Predictors of mortality in silicosis. Respir Med. 1992 ; 86 : 115-9.

P.636 掲載の参考文献

1) 労働者健康福祉機構 (編). アスベスト関連疾患日常診療ガイド増補改訂版. 東京 : 労働調査会 ; 2006.

2) アスベスト (石綿) 関連疾患. https://www.erca.go.jp/asbestos/what/higai/shikkan.html 独立行政法人環境再生保全機構ホームページ.

3) 岸本卓巳. アスベスト肺の診断. 日本内科学会雑誌. 2007 ; 96 : 232-8.

4) 芦澤和人, 他. 石綿肺. 日本胸部臨床. 2014 ; 73 : 1416-23.

5) 森永謙二, 他. 石綿肺患者の予後に関する研究. 日災医誌. 1990 ; 38 : 647-52.

P.638 掲載の参考文献

1) Abe A, et al. Studies on Pneumoconiosis Caused by Organic Dusts. J Science of Labour. 1967 ; 43 : 19-41.

2) Yoshii C, et al. Welder's Pneumoconiosis-Pulmonary Disease Caused by Inhalation of Welding Fumes-. J Aerosol Res. 2005 ; 20 : 238-42.

3) Moriyama H, et al. Two-dimensional analysis of elements and mononuclear cells in hard metal lung disease. Am J Respir Crit Care Med. 2007 ; 176 : 70-7.

P.642 掲載の参考文献

1) 日本職業・環境アレルギー学会 (監). 職業性アレルギー疾患診療ガイドライン 2016. 東京 : 協和企画 ; 2016.

2) 一般社団法人日本アレルギー学会喘息ガイドライン専門部会 (監). 喘息予防・管理ガイドライン 2015. 東京 : 協和企画 ; 2015.

3) Mapp CE, et al. Occupational asthma. Am J Respir Crit Care Med. 2005 ; 172 : 280-305.

4) Olivieri M, et al. Omalizumab in persistent severe bakers, asthma. Allergy. 2008 ; 63 : 790-1.

5) 土橋邦生. 職業性喘息の新しい概念. 呼吸器科. 2006 ; 9 : 564-76.

P.646 掲載の参考文献

1) Ishii H, et al. Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis : a retrospective cohort study in Japan. BMC Pulm Med. 2014 ; 14 : 37.

2) Trapnell BC, et al. Pulmonary alveolar proteinosis. N Engl J Med. 2003 ; 349 : 2527-39.

3) Inoue Y, et al. Japanese Center of the Rare Lung Diseases Consortium. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008 ; 177 : 752-62.

4) Ishii H, et al. Japanese Center of the Rare Lung Disease Consortium. Comparative study of high-resolution CT findings between autoimmune and secondary pulmonary alveolar proteinosis. Chest. 2009 ; 136 : 1348-55.

5) Seymour JF, et al. Pulmonary alveolar proteinosis : progress in the first 44 years. Am J Respir Crit Care Med. 2002 ; 166 : 215-35.

6) Ishii H, et al. Clinical features of secondary pulmonary alveolar proteinosis : pre-mortem cases in Japan. Eur Respir J. 2011 ; 37 : 465-8.

P.651 掲載の参考文献

1) Hayashida M, et al. The epidemiology of lymphangioleiomyomatosis in Japan : a nationwide cross-sectional study of presenting features and prognostic factors. Respirology. 2007 ; 12 : 523-30.

2) 瀬山邦明. 17. リンパ脈管筋腫症. 日本内科学会雑誌. 2012 ; 101 : 2757-65.

3) 林田美江, 他. リンパ脈管筋腫症lymphangioleiomyomatosis (LAM) 診断基準. 日本呼吸器学会雑誌. 2008 ; 46 : 425-7.

4) McCormack FX, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines : Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med. 2016 ; 194 : 748-61.

5) Gupta N, et al. Lymphangioleiomyomatosis Diagnosis and Management : High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2017 ; 196 : 1337-48.

P.653 掲載の参考文献

1) Castellana G, et al. Pulmonary alveolar microlithiasis : review of the 1022 cases reported worldwide. Eur Respir Rev. 2015 ; 24 : 607-20.

2) 立花暉夫. わが国における肺胞微石症. medicina. 1976 ; 13 : 804-5.

3) 日本呼吸器学会 (監). 難治性びまん性肺疾患診療の手引き. 東京 : 南江堂 ; 2017.

4) Mikhailov V. [Pulmonary alveolar microlithiasis and interstitial diffusion]. Klin Med (Mosk). 1954 ; 32 : 31-6.

5) Huqun, et al. Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med. 2007 ; 175 : 263-8.

6) Corut A, et al. Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am J Hum Genet. 2006 ; 79 : 650-6.

7) 萩原弘一. 肺胞微石症の成因と治療. 日本胸部臨床. 2008 ; 67 : 294-302.

8) Saito A, et al. Modeling pulmonary alveolar microlithiasis by epithelial deletion of the Npt2b sodium phosphate cotransporter reveals putative biomarkers and strategies for treatment. Sci Transl Med. 2015 ; 7 : 313ra181.

P.655 掲載の参考文献

1) 吉村邦彦, 他. わが国の嚢胞性線維症 (cystic fibrosis) 患者の病態解析と新規治療の検討. 厚生労働科学研究費補助金 (難治性疾患等克服研究事業) 総合分担研究報告書. 2014 ; 343-9.

2) Rowe SM, et al. Cystic fibrosis. N Engl J Med. 2005 ; 352 : 1992-2001.

P.657 掲載の参考文献

1) Ioachimescu OC, et al. Idiopathic pulmonary haemosiderosis revisited. Eur Respir J. 2004 ; 24 : 162-70.

2) Ohga S, et al. Idiopathic pulmonary haemosiderosis in Japan : 39 possible cases from a survey questionnaire. Eur J Pediatr. 1995 ; 154 : 994-5.

3) Doi T, et al. Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis. Eur J Pediatr. 2013 ; 172 : 1475-81.

4) Chen XY, et al. Idiopathic pulmonary hemosiderosis in adults : Review of cases reported in the latest 15 years. Clin Respir J. 2017 ; 11 : 677-81.

5) Miwa S, et al. Prognosis in Adult Patients with Idiopathic Pulmonary Hemosiderosis. Intern Med. 2011 ; 50 : 1803-8.

P.659 掲載の参考文献

1) Pusey CD. Anti-glomerular basement membrane disease. Kidney Int. 2003 ; 64 : 1535-50.

2) Niles JL, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med. 1996 ; 156 : 440-5.

3) Levy JB, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004 ; 66 : 1535-40.

4) Levy JB, et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001 ; 134 : 1033-42.

5) Jayne DR, et al. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int. 1990 ; 37 : 965-70.

P.663 掲載の参考文献

1) Kamada T, et al. Three-dimensional imaging forced oscillation technique to assess position-dependent airway obstruction in relapsing polychondritis : A case report. Respir Investig. 2017 ; 55 : 69-73.

P.664 掲載の参考文献

1) Dixon GF, et al. Clinical commentary : Advances in the diagnosis and treatment of broncholithiasis. Am Rev Respir Dis. 1984 ; 129 : 1028-30.

2) 朝川勝明, 他. 気管支結石症. 日本胸部臨床. 2012 ; 71 : S291-5.

3) 田中希宇人, 他. 喀石により喀血が消失した気管支結石症の1例. 気管支学. 2013 ; 35 : 140-4.

P.667 掲載の参考文献

1) Siewert AK. Uber einem Fall von Bronchiectasie bei einem Patienten mit Situs inversus viscerum. Berliner klinische Wochenschrift. 1904 ; 41 : 139-41.

2) Kartagener M. Zur Pathogenese der Bronchiektasien. I. Mitteilung : Bronchiektasien bei Situs viscerum inversus. Beitrage zur Klinik und Erforschung der Tuberkulose und der Lungenkrankenheiten. 1933 ; 83 : 489-501.

3) Afzelius BA. A human syndrome caused by immotile cilia. Science. 1976 ; 193 : 317-9.

4) Spassky N, et al. The development and functions of multiciliated epithelia. Nat Rev Mol Cell Biol. 2017 ; 18 : 423-36.

5) Werner C, et al. Diagnosis and management of primary ciliary dyskinesia. Cilia. 2015 ; 4 : 2.

6) Leigh MW, et al. The challenges of diagnosing primary ciliary dyskinesia. Proc Am Thorac Soc. 2011 ; 8 : 434-7.

7) Leigh MW, et al. Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia. Ann Am Thorac Soc. 2013 ; 10 : 574-81.

8) Yoshioka D, et al. Primary ciliary dyskinesia that responded to long-term, low-dose clarithromycin. Intern Med. 2010 ; 49 : 1437-40.

9) Kido T, et al. Two cases of primary ciliary dyskinesia with different responses to macrolide treatment. Intern Med 2012 ; 51 : 1093-8.

10) Shapiro AJ, et al. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia : PCD foundation consensus recommendations based on state of the art review. Pediatr Pulmonol. 2016 ; 51 : 115-32.

11) Kobbernagel HE, et al. Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesia. BMC Pulm Med. 2016 ; 16 : 104.

12) U. S. National Library of Medicine. Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia (CLEAN-PCD). https://clinicaltrials.gov/ct2/show/NCT02871778

P.672 掲載の参考文献

1) 国立研究開発法人国立がん研究センター. 2015年のがん罹患数, 死亡数予測. http://ganjoho.jp/reg_stat/statistics/stat/summary.html

2) 公益財団法人がん研究振興財団. がんの統計 '16. http://ganjoho.jp/reg_stat/statistics/brochure/backnumber/2016_jp.html

3) Lichtenstein P, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000 ; 343 : 78-85.

4) 津金昌一郎. 肺癌の疫学危険因子環境・職業関連要因. 日本臨床. 2013 ; 71 : 65-73.

5) Wakai K, et al. Decrease in risk of lung cancer death in Japanese men after smoking cessation by age at quitting : pooled analysis of three large-scale cohort studies. Cancer Sci. 2007 ; 98 : 584-9.

P.675 掲載の参考文献

1) Spiro SG, et al. Initial evaluation of the patient with lung cancer : symptoms, signs, laboratory tests, and paraneoplastic syndromes : ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007 ; 132 (3 Suppl) : 149S-160S.

2) 高山浩一, 他. 大学病院を受診した肺癌患者の受診契機に関する後方視的解析. 日呼吸誌. 2013 ; 2 : 85-91.

3) Oken MM, et al. Screening by chest radiograph and lung cancer mortality : the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011 ; 306 : 1865-73.

4) 日本肺癌学会 (編). 肺癌集団検診ガイドライン. https://www.haigan.gr.jp/uploads/photos/249.pdf

5) National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 ; 365 : 395-409.

P.679 掲載の参考文献

1) 日本肺癌学会 (編). EBMの手法による肺癌診療ガイドライン 2017年版. 東京 : 金原出版 ; 2017.

2) 日本肺癌学会 (編). 肺癌取扱い規約第8版. 東京 : 金原出版 ; 2017.

3) 日本肺癌学会 (編). 肺癌取扱い規約第7版. 東京 : 金原出版 ; 2010.

4) Eberhardt WE, et al. The IASLC Lung Cancer Staging Project : Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2015 ; 10 : 1515-22.

5) Stahel RA, et al. Staging and prognostic factors in small cell lung cancer : A consensus report. Lung Cancer. 1989 ; 5 : 119-26.

6) Niho S, et al. Clinical outcome of chemoradiation therapy in patients with limited-disease small cell lung cancer with ipsilateral pleural effusion. J Thorac Oncol. 2008 ; 3 : 723-7.

P.683 掲載の参考文献

1) Travis WD, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Fourth edition. Lyon : IARC press ; 2015.

2) Kreyberg L, et al. Histological Typing of Lung Tumours, 1st ed. Geneva : World Health Organization ; 1967.

3) Travis WD, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6 : 244-85, 2011

4) Tsao MS. et al. IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer. Aurora : IASLC publication ; 2017.

P.689 掲載の参考文献

1) Travis WD, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Fourth edition. Lyon : IARC press ; 2015.

2) Travis WD, et al. WHO Classification of Tumours, Pathology & Genetics, Tumours of the Lung, Pleura, Thymus and Heart. Lyon : IARC press ; 2004.

3) Noguchi M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995 ; 75 : 2844-52.

4) Amin MB, et al. Micropapillary component in lung adenocarcinoma : a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol. 2002 ; 26 : 358-64.

5) Inamura K, et al. Pulmonary adenocarcinomas with enteric differentiation : histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol. 2005 ; 29 : 660-5.

6) Travis WD, et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 ; 6 : 244-85.

7) Yoshizawa A, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma : prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011 ; 24 : 653-64.

8) Yatabe Y, et al. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 2002 ; 26 : 767-73.

9) Sumiyoshi S, et al. Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages. Lung Cancer. 2013 ; 81 : 53-9.

P.692 掲載の参考文献

1) Travis WD, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Fourth edition. Lyon : IARC press ; 2015.

2) Brambilla E, et al. Basal cell (basaloid) carcinoma of the lung : a new morphologic and phenotypic entity with separate prognostic significance. Hum Pathol. 1992 ; 23 : 993-1003.

3) Brambilla C, et al. Lung squamous cell carcinomas with basaloid histology represent a specific molecular entity. Clin Cancer Res. 2014 ; 20 : 5777-86.

4) Kadota K, et al. A Grading System Combining Tumor Budding and Nuclear Diameter Predicts Prognosis in Resected Lung Squamous Cell Carcinoma. Am J Surg Pathol. 2017 ; 41 : 750-60.

5) Kadota K, et al. Tumor Spread Through Air Spaces Is an Independent Predictor of Recurrence-free Survival in Patients With Resected Lung Squamous Cell Carcinoma. Am J Surg Pathol. 2017 ; 41 : 1077-86.

P.695 掲載の参考文献

1) Travis WD, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Fourth edition. Lyon : IARC press ; 2015.

2) Travis WD, et al. WHO Classification of Tumours, Pathology & Genetics, Tumours of the Lung, Pleura, Thymus and Heart. Lyon : IARC press ; 2004.

3) Travis WD, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998 ; 22 : 934-44.

4) Kreyberg L. Histological Typing of Lung Tumours, 2nd ed. Geneva : World Health Organization ; 1981.

P.699 掲載の参考文献

1) Travis WD, et al. WHO Classification of Tumours, Pathology & Genetics, Tumours of the Lung, Pleura, Thymus and Heart. Lyon : IARC press ; 2004.

2) Travis WD, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Fourth edition. Lyon : IARC press ; 2015.

3) Bastide K, et al. Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level? Lung Cancer. 2010 ; 68 : 1-9.

4) Ho JC, et al. Lymphoepithelioma-like carcinoma of the lung. Respirology. 2006 ; 11 : 539-45.

5) French CA. NUT midline carcinoma. Cancer Genet Cytogenet. 2010 ; 203 : 16-20.

P.709 掲載の参考文献

1) Sawabata N, et al. Risk assessment of lung resection for lung cancer according to pulmonary function : republication of systematic review and proposals by guideline committee of the Japanese association for chest surgery 2014. Gen Thorac Cardiovasc Surg. 2015 ; 63 : 14-21.

2) Ginsberg RJ, et al. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995 ; 60 : 615-22.

3) Albain KS, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer : a phase III randomised controlled trial. Lancet. 2009 ; 374 : 379-86.

4) Pignon JP, et al. LACE Collaborative Group. Lung adjuvant cisplatin evaluation : a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008 ; 26 : 3552-9.

5) Masuda M, et al. Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery. Thoracic and cardiovascular surgery in Japan during 2014 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2016 ; 64 : 665-97.

6) Sawabata N, et al. Japanese Joint Committee for Lung Cancer Registration. Japanese lung cancer registry study of 11,663 surgical cases in 2004 : demographic and prognosis changes over decade. J Thorac Oncol. 2011 ; 6 : 1229-35.

7) Sato T, et al. Japanese Association for Chest Surgery. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2014 ; 147 : 1604-11.

P.713 掲載の参考文献

1) 日本肺癌学会. EBM の手法による肺癌診療ガイドライン 2016年版. 東京 : 金原出版 ; 2016.

2) Sperduto PW, et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases : An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2017 ; 3 : 827-31.

P.718 掲載の参考文献

1) Scagliotti GV, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 ; 26 : 3543-51.

2) Paz-Ares L, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT) : a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 ; 13 : 247-55.

3) Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 ; 355 : 2542-50.

4) Zhou C, et al. BEYOND : A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 ; 33 : 2197-204.

5) Barlesi F, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer : AVAPERL (MO22089). J Clin Oncol. 2013 ; 31 : 3004-11.

6) Barlesi F, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous non-small-cell lung cancer : updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014 ; 25 : 1044-52.

7) Patel JD, et al. PointBreak : a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 ; 31 : 4349-57.

8) Gandhi L, et al. KEYNOTE-189 Investigators. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018 ; 378 : 2078-92.

9) Socinski MA, et al. IMpower150 Study Group. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018 ; 378 : 2288-301.

10) Shepherd FA, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000 ; 18 : 2095-103.

11) Garon EB, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL) : a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014 ; 384 : 665-73.

12) Yoh K, et al. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer. 2016 ; 99 : 186-93.

13) Hanna N, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 ; 22 : 1589-97.

14) Nokihara H, et al. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol. 2017 ; 28 : 2698-706.

15) Baggstrom MQ, et al. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer : a meta-analysis. J Thorac Oncol. 2007 ; 2 : 845-53.

16) Okamoto I, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer : results of a west Japan oncology group study. J Clin Oncol. 2010 ; 28 : 5240-6.

17) Yoshioka H, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer : updated results of the West Japan Oncology Group LETS study. Ann Oncol. 2013 ; 24 : 1326-31.

18) Kubota K, et al. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer : TCOG0701 CATS trial. Ann Oncol. 2015 ; 26 : 1401-8.

19) Socinski MA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer : final results of a phase III trial. J Clin Oncol. 2012 ; 30 : 2055-62.

20) Paz-Ares L, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018 ; 379 : 2040-51.

21) Jotte RM, et al. IMpower131 : Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. 2018 ASCO Annual Meeting. J Clin Oncol. 2018 ; 36 (suppl ; abstr LBA9000).

22) Scagliotti G, et al. The differential efficacy of pemetrexed according to NSCLC histology : a review of two Phase III studies. Oncologist. 2009 ; 14 : 253-63.

23) 日本肺癌学会 (編). EBMの手法による肺癌診療ガイドライン 2016年版 (第4版). 東京 : 金原出版 ; 2016.

24) Gridelli C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer : the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003 ; 95 : 362-72.

25) Kudoh S, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer : results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006 ; 24 : 3657-63.

26) Hata A, et al. Pemetrexed monotherapy for chemo-naive elderly (aged > 80) patients with non-squamous non-small cell lung cancer : results from combined analysis of two single arm phase II studies (HANSHIN002 and 003). Cancer Chemother Pharmacol. 2017 ; 79 : 689-95.

27) Baka S, et al. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer. 2008 ; 99 : 442-7.

28) Pujol JL, et al. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer. 2000 ; 83 : 8-15.

29) Noda K, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 ; 346 : 85-91.

30) Jiang L, et al. Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer : a metaanalysis. Clin Lung Cancer. 2007 ; 8 : 497-501.

31) Jiang J, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol. 2010 ; 5 : 867-73.

32) Okamoto H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer : JCOG 9702. Br J Cancer. 2007 ; 97 : 162-9.

33) O'Brien ME, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006 ; 24 : 5441-7.

34) von Pawel J, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999 ; 17 : 658-67.

35) von Pawel J, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014 ; 32 : 4012-9.

36) Masuda N, et al. CPT-11 : a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992 ; 10 : 1225-9.

37) Inoue A, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer : North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 2008 ; 26 : 5401-6.

38) Jotte R, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol. 2011 ; 29 : 287-93.

P.723 掲載の参考文献

1) Janne PA, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015 ; 372 : 1689-99.

2) Sullivan I, et al. ALK inhibitors in non-small cell lung cancer : the latest evidence and developments. Ther Adv Med Oncol. 2016 ; 8 : 32-47.

3) 日本肺癌学会 (編). EBM の手法による肺癌診療ガイドライン 2016年版 (第4版). 東京 : 金原出版 ; 2016.

4) Park K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive nons-mall-cell lung cancer (LUX-Lung 7) : a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 ; 17 : 577-89.

5) Soria JC, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 ; 378 : 113-25.

6) Kwak EL, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 ; 363 : 1693-703.

7) Peters S, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017 ; 377 : 829-38.

8) Hida T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX) : an open-label, randomised phase 3 trial. Lancet. 2017 ; 390 : 29-39.

9) Soria JC, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4) : a randomised, open-label, phase 3 study. Lancet. 2017 ; 389 : 917-29.

10) Shaw AT, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer : a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016 ; 17 : 234-42.

11) Crino L, et al. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib : Results From ASCEND-2. J Clin Oncol. 2016 ; 34 : 2866-73.

12) Katayama R, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res. 2014 ; 20 : 5686-96.

13) Besse B, et al. Lorlatinib in patients (Pts) with previously treated ALK + advanced non-small cell lung cancer (NSCLC) : Updated efficacy and safety. 2018 ASCO Annual Meeting. J Clin Oncol. 2018 ; 36.

14) Rossi G, et al. Detection of ROS1 rearrangement in non-small cell lung cancer : current and future perspectives. Lung Cancer (Auckl). 2017 ; 8 : 45-55.

15) Shaw AT, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 ; 371 : 1963-71.

16) Wu X, et al. Gaining insight into crizotinib resistance mechanisms caused by L2026M and G2032R mutations in ROS1 via molecular dynamics simulations and free-energy calculations. J Mol Model. 2017 ; 23 : 141.

17) Drilon A, et al. A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. Clin Cancer Res. 2016 ; 22 : 2351-8.

18) 石井暢也. やっと来たがん分子標的の大物, MEK/RAF MAPK経路阻害薬の研究開発. 日本薬理学雑誌. 2013 ; 141 : 15-21.

19) Marchetti A, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011 ; 29 : 3574-9.

20) Planchard D, et al. Dabrafenib plus trametinib in patients with previously treated BRAF (V600E) -mutant metastatic non-small cell lung cancer : an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 ; 17 : 984-93.

21) Planchard D, et al. Updated survival of patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. J Clin Oncol. 2017 ; 35 Suppl : 9075

P.728 掲載の参考文献

1) Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 ; 366 : 2443-54.

2) Brahmer J, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 ; 373 : 123-35.

3) Borghaei H, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 ; 373 : 1627-39.

4) Hellmann MD, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018 ; 378 : 2093-104.

5) Borghaei H, et al. Nivolumab + Ipilimumab, Nivolumab + Chemotherapy, and Chemotherapy in Chemo-Naive Patients With Advanced Non-Small Cell Lung Cancer and < 1% Tumor PD-L1 Expression : Results From CheckMate 227. J Clin Oncol. 2018 ; 36 suppl : Abstr 9001.

6) Herbst RS, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : a randomised controlled trial. Lancet. 2016 ; 387 : 1540-50.

7) Reck M, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 ; 375 : 1823-33.

8) Langer CJ, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer : a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 ; 17 : 1497-508.

9) Gandhi L, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018 ; 378 : 2078-92.

10) Paz-Ares L, et al. KEYNOTE-407 : Phase 3 Study of Carboplatin-Paclitaxel/Nab-Paclitaxel With or Without Pembrolizumab for Metastatic Squamous NSCLC. J Clin Oncol. 2018 ; 36 suppl : Abstr 105.

11) Rittmeyer A, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK) : a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 ; 389 : 255-65.

12) Socinski MA, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018 ; 378 : 2288-301.

13) Jotte R, et al. IMPower131 : Primary PFS and Safety Analysis of a Randomized Phase III Study of Atezolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel vs Carboplatin + Nab-Paclitaxel as 1L Therapy in Advanced Squamous NSCLC. J Clin Oncol. 2018 ; 36 suppl : Abstr 9000.

14) Antonia SJ, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 ; 377 : 1919-29.

P.733 掲載の参考文献

1) NCCNガイドライン (NCCN Clinical Practice Guidelines in Oncology) http://www.nccn.org/

2) ASCO (American Society Clinical Oncology) ガイドライン http://www.asco.org/

3) MASCC (Multinational Association of Supportive Care in Cancer) ガイドライン http://www.mascc.org/

4) 日本癌治療学会 (編). 制吐薬適正使用ガイドライン第2版. 東京 : 金原出版 ; 2015.

5) 日本癌治療学会 (編). G-CSF適正使用ガイドライン第2版. 東京 : 金原出版 ; 2013.

6) 日本臨床腫瘍学会 (編). 発熱性好中球減少症 (FN) 診療ガイドライン. 東京 : 南江堂 ; 2012.

7) 厚生労働省/難治性の肝・胆道疾患に関する調査研究班, 肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究班. 免疫抑制・化学療法により発症するB型肝炎対策ガイドライン. 2011.

P.737 掲載の参考文献

1) 日本肺癌学会 (編). 肺癌取扱い規約第8版. 東京 : 金原出版 ; 2017.

2) Travis WD, et al. eds. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th edition. Geneve : World Health Organization ; 2015.

P.742 掲載の参考文献

1) Chudgar NP, et al. Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. J Thorac Cardiovasc Surg. 2017 ; 154 : 319-30.

2) Moorcraft SY, et al. Molecular profiling of colorectal pulmonary metastases and primary tumours : implications for targeted treatment. Oncotarget. 2017 ; 8 : 64999-5008.

3) Thomford NR, et al. The surgical treatment of metastatic tumors in the lungs. J Thorac Cardiovasc Surg. 1965 ; 49 : 357-63.

4) Pastorino U, et al. Long-term results of lung metastasectomy : prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997 ; 113 : 37-49.

5) Murakawa T, et al. Thoracoscopic surgery versus open surgery for lung metastases of colorectal cancer : a multi-institutional retrospective analysis using propensity score adjustment. Eur J Cardiothorac Surg. 2017 ; 51 : 1157-63.

6) Kawakita N, et al. Indocyanine Green Fluorescence Navigation Thoracoscopic Metastasectomy for Pulmonary Metastasis of Hepatocellular Carcinoma. Ann Thorac Cardiovasc Surg. 2016 ; 22 : 367-9.

7) Chen-Yoshikawa TF, et al. Clinical application of projection mapping technology for surgical resection of lung metastasis. Interact Cardiovasc Thorac Surg. 2017 ; 25 : 1010-1.

8) Chen-Yoshikawa TF, et al. Update on three-dimensional image reconstruction for preoperative simulation in thoracic surgery. J Thorac Dis. 2016 ; 8 (Suppl 3) : S295-301.

P.747 掲載の参考文献

1) Guo Y, et al. Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck : Results of an open-label, single-arm, multicenter trial. Head Neck. 2015 ; 37 : 1081-7.

2) Chen F, et al. Pulmonary resection for metastatic head and neck cancer. World J Surg. 2008 ; 32 : 1657-62.

3) Chen F, et al. Lung metastasectomy for colorectal carcinoma in patients with a history of hepatic metastasis. Ann Thorac Cardiovasc Surg. 2011 ; 17 : 13-8.

4) Onaitis MW, et al. Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg. 2009 ; 87 : 1684-8.

5) Nakajima J, et al. Metastatic Lung Tumor Study Group of Japan. Recent improvement of survival prognosis after pulmonary metastasectomy and advanced chemotherapy for patients with colorectal cancer. Eur J Cardiothorac Surg. 2017 ; 51 : 869-73.

6) Chen F, et al. Pulmonary resection for metastasis from esophageal carcinoma. Interact Cardiovasc Thorac Surg. 2008 ; 7 : 809-12.

7) Chen F, et al. Pulmonary Resection for metastases from hepatocellular carcinoma. World J Surg. 2008 ; 32 : 2213-7.

8) 安川元章, 他. 膵癌肺転移に対する9切除例の検討. 日本呼吸器外科学会雑誌. 2016 ; 30 : 540-4.

9) Arnaoutakis GJ, et al. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis : an analysis of outcomes and survival. J Gastrointest Surg. 2011 ; 15 : 1611-7.

10) Anraku M, et al. Pulmonary metastases from uterine malignancies : results of surgical resection in 133 patients. J Thorac Cardiovasc Surg. 2004 ; 127 : 1107-12.

11) Naito S, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era : a cooperative group report of 1463 patients. Eur Urol. 2010 ; 57 : 317-25.

12) National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for breast cancer.

13) Chen F, et al. Clinical features of surgical resection for pulmonary metastasis from breast cancer. Eur J Surg Oncol. 2009 ; 35 : 393-7.

14) Digesu CS, et al. Management of Sarcoma Metastases to the Lung. Surg Oncol Clin N Am. 2016 ; 25 : 721-33.

15) Chen F, et al. Significance of tumor recurrence before pulmonary metastasis in pulmonary metastasectomy for soft tissue sarcoma. Eur J Surg Oncol. 2009 ; 35 : 660-5.

P.749 掲載の参考文献

1) 日本肺癌学会. 肺癌取扱い規約第8版. 東京 : 金原出版 ; 2017.

2) Travis WD, et al. WHO Classification of Tumours of the Lung, Pleural, Thymus and Heart. 4th ed. IARC : 2015.

3) Annual Report, Thoracic and cardiovascular surgery in Japan. Gen Thorac Cardiocasc Surg. 2010-2014.

P.753 掲載の参考文献

1) Travis WD, et al. WHO Histological Classification of Tumours. Histological Typing of Lung and Pleural Tumours. 3rd ed. IARC ; 1999.

2) Travis WD, et al. WHO Classification of Tumours of the Lung, Pleural, Thymus and Heart. 4th ed. IARC ; 2015.

3) Miyoshi R, et al. Expression of p16INK4a in mixed squamous cell and glandular papilloma of the lung. Pathol Int. 2017 ; 67 : 306-10.

P.757 掲載の参考文献

1) Travis WD, et al. WHO Classification of Tumours of the Lung, Pleural, Thymus and Heart. 4th ed. IARC. 2015.

P.759 掲載の参考文献

1) Travis WD, et al. WHO Classification of Tumours of the Lung, Pleural, Thymus and Heart. 4th ed. IARC ; 2015.

P.760 掲載の参考文献

1) Travis WD, et al. WHO Classification of Tumours of the Lung, Pleural, Thymus and Heart. 4th ed. IARC ; 2015.

P.763 掲載の参考文献

1) Pryce DM, et al. Intralobar sequestration of lung associated with an abnormal pulmonary artery. Br J Surg. 1947 ; 35 : 18-29.

2) 藤井義敬. その他の外科的肺疾患. 先天性異常. 呼吸器外科学第4版. 正岡昭 (監). 東京 : 南山堂 ; 2009. pp. 292-302.

3) Munetaka M, et al. Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery. Thoracic and cardiovascular surgery in Japan during 2014. Gen Thorac Cardiovasc Surg. 2016 ; 64 : 665-97.

4) 松脇りえ, 他. 先天性異常・形成不全. 肺分画症. 呼吸器疾患最新の治療 2016-2018. 杉山幸比古, 他 (編). 東京 : 南江堂 ; 2016. pp. 413-5.

5) Long Q, et al. Evaluation of pulmonary sequestration with multidetector computed tomography angiography in a select cohort of patients : A retrospective study. Clinics (Sao Paulo). 2016 ; 71 : 392-8.

6) Kestenholz PB, et al. Thoracoscopic treatment of pulmonary sequestration. Eur J Cardiothorac Surg. 2006 ; 29 : 815-8.

P.765 掲載の参考文献

1) 小川純一, 他. 肺底区動脈大動脈起始症に対し肺動脈再建を行った1例. 胸部外科. 1985 ; 38 : 316-21.

2) 江崎紀浩, 他. 肺底動脈大動脈起始症が高齢 (69歳) で発見された1例と本邦症例のまとめ. 日呼学会誌. 2011 ; 49 : 528-33.

3) Yamanaka A, et al. Anomalous systemic arterial supply to normal basel segments of the left lower lobe. Ann Thorac Surg. 1999 ; 68 : 332-8.

4) Rubin EM, et al. Fatal massive hemoptysis secondary to intralobar sequestration. Chest. 1994 ; 106 : 954-5.

5) Hessel EA 2nd, et al. High systemic origin of the sole artery to the basal segments of the left lung : findings, surgical treatment, and embryologic interpretation. Surgery 1970 ; 67 : 624-32.

6) 前川信一, 他. 肺切除を伴わず異常動脈遮断のみ施行した左肺底動脈大動脈起始症の1例. 日呼外会誌. 2013 ; 27 : 460-4.

P.768 掲載の参考文献

1) Ch'In KY, et al. Congenital adenomatoid malformation of one lobe of a lung with general anasarca. Arch Pathol (Chic). 1949 ; 48 : 221-9.

2) Stocker JT, et al. Congenital cystic adenomatoid malformation of the lung. Classification and morphologic spectrum. Hum Pathol. 1977 ; 8 : 155-71.

3) 萱野公一, 他. 成人の先天性嚢胞性腺腫様奇形 (congenital cystic adenomatoid malformation : CCAM) で胸腔鏡下に右肺中葉切除術を施行した1例. 日本呼吸器外科学会雑誌. 1995 ; 9 : 849-53.

4) 倉島庸, 他. 乳児期に発症した先天性嚢胞性腺腫様奇形の1例. 日本呼吸器外科学会雑誌. 2000 ; 14 : 727-42.

P.770 掲載の参考文献

1) Kameyama K, et al. Congenital bronchial atresia associated with spontaneous pneumothorax. Ann Thorac Surg. 2006 ; 82 : 1497-9.

2) Nussbaumer-Ochsner Y, et al. Finger-in-glove sign in bronchial atresia. Thorax. 2011 ; 66 : 182.

3) Ramsay BH, et al. Mucocele, congenital bronchiectasis, and bronchiogenic cyst. J Thorac Surg. 1953 ; 26 : 21-30.

4) 山口学, 他. 長期間経過観察されていた先天性気管支閉鎖症の一手術例. 日呼外会誌. 2009 ; 23 : 613-6.

5) Tanaka K, et al. Recurrent pneumothorax associated with bronchial atresia : report of a case. Surg Today. 2015 ; 45 : 1326-9.

6) 市橋匠, 他. 気管支閉鎖症の4例. 気管支学. 1998 ; 20 : 472-80.

7) 木田陽子, 他. 3次元CTを用いて診断した先天性気管支閉鎖症の1例. 気管支学, 2013 ; 35 : 296-9.

8) 大越祐介, 他. 閉塞性肺炎を来した気管支閉鎖症の一手術例. 日呼外会誌. 2017 ; 31 : 160-4.

P.774 掲載の参考文献

1) Andersen PE, et al. Interventional treatment of pulmonary arteriovenous malformations. World J Radiol. 2010 ; 28 : 339-44.

2) Jaskolka J, et al. Imaging of hereditary hemorrhagic telangiectasia. AJR Am J Roentgenol. 2004 ; 183 : 307-14.

3) Gossage JR, et al. Pulmonary Arteriovenous Malformation. A state of the art review. Am J Respir Crit Care Med. 1998 ; 158 : 643-61.

4) Nakayama M, et al. Prevalence of Pulmonary Arteriovenous Malformations as Estimated by Low-Dose Thoracic CT Screening. Intern Med. 2012 ; 51 : 1677-81.

5) van Gent MW, et al. Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia : a transthoracic contrast echocardiography study. Chest. 2010 ; 138 : 833-9.

6) 奥田昌也, 他. 孤立性肺動静脈瘻に対する治療戦略の検討. 日呼外会誌. 2008 ; 22 : 987-91.

7) 橋詰直樹, 他. 出血性ショックに至った肺動静脈奇形の1例. 日呼外会誌. 2011 ; 25 : 406-12.

P.777 掲載の参考文献

1) Pinherio PF, et al. Current knowledge on esophageal atresia. World J Gastroenterol. 2012 ; 18 : 3662-72.

2) Braimbridge MV, et al. Oesophago-bronchial fistula in the adult. Thorax. 1965 ; 20 : 226-33.

3) 佐々木高信, 他. 成人の先天性食道気管支瘻の1例. 日呼外会誌. 2015 ; 29 : 673-6.

4) 森山岳, 他. 人間ドックにて偶然発見された先天性気管支食道瘻の1例. 日呼吸会誌. 2001 ; 39 : 888-92.

5) 三野暢哉, 他. 成人の先天性気管支食道瘻の1例. 日呼外会誌. 2003 ; 17 : 511-4.

6) Brunner A, et al. Esophagobronchial fistule. Munch Med Wochenschr. 1961 ; 103 : 2181-4.

7) 大司俊郎, 他. 食道癌放射線治療後の巨大な気管食道瘻に対してカバー付きステントと手術を併用した1例. 日消外会誌. 1999 ; 32 : 2238-42.

P.780 掲載の参考文献

1) ARDS Definition Task Force, et al. Acute respiratory distress syndrome : the Berlin Definition. JAMA. 2012 ; 307 : 2526-33.

2) Bernard GR, et al. Report of the American-European Consensus conference on acute respiratory distress syndrome : definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee. J Crit Care. 1994 ; 9 : 72-81.

3) 3学会合同ARDS診療ガイドライン2016作成委員会 (編). ARDS診療ガイドライン 2016. 東京 : 日本呼吸器学会 ; 2016.

P.785 掲載の参考文献

1) 日本循環器学会, 他. 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). 2018.

2) 日本循環器学会, 他. 肺高血圧症治療ガイドライン (2017年改訂版). 2018.

3) Konstantinides SV, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 ; 35 : 3033-69.

4) 日本循環器学会, 他. 慢性肺動脈血栓塞栓症に対するballoon pulmonary angioplastyの適応と実施法に関するステートメント (2014年版).

P.788 掲載の参考文献

1) O'Driscoll BR, et al. BTS guideline for emergency oxygen use in adult patients. Thorax. 2008 ; 63 Suppl 6 : p. vi1-68. doi : 10.1136/thx.2008.102947.

2) Nava S, et al. Non-invasive ventilation in acute respiratory failure. Lancet. 2009 ; 374 : 250-9.

P.793 掲載の参考文献

1) 坪井知正. 非侵襲的換気療法-ガイドラインの作成に向けて ; NPPVの予後への影響のEvidence. 呼吸と循環. 2003 ; 51 : 47-56.

2) Nickol AH, et al. Mechanisms of improvement of respiratory failure in patients with restrictive thoracic disease treated with non-invasive ventilation. Thorax. 2005 ; 60 : 754-60.

3) 日本呼吸器学会肺生理専門委員会在宅呼吸ケア白書ワーキンググループ. 在宅呼吸ケア白書 2010.

4) 坪井知正, 他. 鼻マスク陽圧換気法を長期人工呼吸療法として導入した慢性呼吸不全41症例の検討. 日胸疾会誌. 1996 ; 34 : 959-67.

5) Appendini L, et al. Physiologic effects of positive end-expiratory pressure and mask pressure support during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994 ; 149 : 1069-76.

P.800 掲載の参考文献

1) 大井元晴. 睡眠呼吸障害の歴史定義と考え方. Medicina. 2011 ; 48 : 924-27.

2) International classification of sleep disorders, 3rd ed. American Academy of Sleep Medicine. IL, 2014.

3) Harper RM, et al. The role of the tongue in sleep apnea. In : Guilleminault C, Dement WC, editors. Sleep apnea syndrome. New York : Alan R Liss ; 1978. pp219-34.

4) Jordan AS, et al. Adult obstructive sleep apnoea. Lancet. 2014 ; 383 : 736-47.

5) Sullivan CE, et al. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet. 1981 ; 1 : 862-5.

6) Peppard PE, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000 ; 284 : 3015-21.

7) Bradley TD, et al. Sleep apnea and heart failure : Part II : central sleep apnea. Circulation. 2003 ; 107 : 1822-6.

8) 日本呼吸器学会NPPVガイドライン作成委員会 (編). NPPV (非侵襲的陽圧換気療法) ガイドライン改訂第2版. 東京 : 南江堂 ; 2015.

9) 大井元晴, 他. 呼吸不全の病態眠時呼吸異常. 結核. 1988 ; 63 : 54-8.

10) Berry RB, et al. The AASM manual for the scoring of sleep and associated events : rules, terminology and technical specifications, Version 2.1. Darien IL : American Academy of Sleep Medicine ; 2014.

11) Masa JF, et al. Restrictive lung disorders. Kryger MH, et al. ed. Principles and practice of sleep medicine. 5th ed. Chapter 112. Philadelphia : Saunders Elsevier ; 2011. pp 1308-17.

12) Kryger MH, et al. Principles and Practice of Sleep Medicine 5th ed. Philadelphia, PA. Saunders ; 2011.

P.803 掲載の参考文献

1) Phillipson EA, et al. Hypoventilation and hyperventilation syndromes. In : Murray JF, et al. eds. Textbook of respiratory medicine. 3rd ed. Philadelphia : W. B. Saunders Company ; 2000. pp. 2139-47.

2) Folgering H. The hyperventilation syndrome. In : Altose MD, et al. eds. Control of breathing in health and disease, New York : Marcel Dekker ; 1999. pp633-60.

3) Laffey JG, et al. Hypocapnia. N Engl J Med. 2002 ; 347 : 43-53.

4) Hornsveld HK, et al. Double-blind placebo-controlled study of the hyperventilation provocation test and the validity of the hyperventilation syndrome. Lancet. 1996 ; 348 : 154-8.

5) 陳和夫. 症例に学ぶ呼吸機能検査 3. 過換気後の低酸素血症. 呼吸. 2007 ; 26 : 644-51.

P.806 掲載の参考文献

1) Duffin J, et al. Hypoventilation and hyperventilation syndromes. Murray & Nadel's Textbook of Respiratory Medicine 5th Edition Volume 2. Section P Disorders in the control of breathing. Chapter 78. Philadelphia : Saunders Elsevier ; 2010. pp. 1859-80.

2) 日本呼吸器学会NPPV ガイドライン作成委員会 (編). NPPV (非侵襲的陽圧換気療法) ガイドライン改訂第2版. 東京 : 南江堂 ; 2015.

P.812 掲載の参考文献

1) Light RW. Pleural effusion, 6th edition. Philadelphia : Wolters Kluwer/Lippincott Williams & Wilkins ; 2013.

2) 公益財団法人結核予防会結核研究所疫学情報センター. 結核の統計. 登録時結核病類別罹患数. 性・年齢階級別 (2016-1987).

3) Valdes L, et al. Diagnosis of tuberculous pleurisy using the biologic parameters adenosine deaminase, lysozyme, and interferon gamma. Chest. 1993 ; 103 : 458-65.

4) Colice GL, et al. Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline. Chest. 2000 ; 118 : 1158-71.

5) Light RW. The Light criteria : the beginning and why they are useful 40 years later. Clin Chest Med. 2013 ; 34 : 21-6.

P.818 掲載の参考文献

1) Colice GL, et al. Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline. Chest. 2000 ; 118 : 1158-71. Review. Erratum in : Chest. 2001 ; 119 : 319.

2) Davies CW, et al. Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the management of pleural infection. Thorax. 2003 ; 58 Suppl 2 : ii18-28.

3) 日本感染症学会, 日本化学療法学会 JAID/JSC感染症治療ガイド・ガイドライン作成委員会呼吸器感染症WG. JAID/JSC感染症治療ガイドライン-呼吸器感染症-. 日本化学療法学会雑誌. 2014 ; 62 : 1-109.

P.821 掲載の参考文献

1) 眞庭謙昌. 術後胸腔内出血-術中における予防と発生時の対応. 胸部外科. 2017 ; 70 : 688-91.

2) Dent DL. A prospective human study of the hematologic, coagulative, and inflammatory characteristics of hemothorax. J Trauma Acute Care Surg. 2017 ; 83 : 908-10.

3) 日本外傷学会, 日本救急医学会 (監). 日本外傷学会外傷初期診療ガイドライン改訂第5版編集委員会 (編). 改訂第5版外傷初期診療ガイドライン JATEC. 東京 : へるす出版 ; 2017.

P.825 掲載の参考文献

1) Saito T, et al. Postoperative Chylotholax ; Intraoperative Prevention and Postoperative Management. Kyobu Geka. 2017 ; 70 : 662-7.

2) Nair SK, et al. Aetiology and management of chylothorax in adults. Eur J Cardiothrac Surg. 2007 ; 32 : 362-9.

3) Bryant AS, et al. The incidence and management of postoperative chylothorax after pulmonary resection and thoracic mediastinal lymph node dissection. Ann Thorac Surg. 2014 ; 98 : 232-5.

4) Valentine VG, et al. The management of chylothorax. Chest. 1992 ; 102 : 586-91.

P.830 掲載の参考文献

1) Noppen M, et al. Pneumothorax. Respiration. 2008 ; 76 : 121-7.

2) Legras A, et al. Pneumothorax in women of child-bearing age : an update classification based on clinical and pathologic findings. Chest. 2014 ; 145 : 354-60.

3) Feller-Kopman D, et al. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg. 2007 ; 84 : 1656-61.

4) 日本気胸・嚢胞性肺疾患学会学術委員会 (編). 気胸・嚢胞性肺疾患-規約・用語ガイドライン第2版. 東京 : 金原出版 ; 2009.

5) MacDuff A, et al. Management of spontaneous pneumothorax : British Thoracic Society pleural disease guideline 2010.

6) Ahmedzai S, et al. British Thoracic Society Standards of Care Committee. Managing passengers with stable respiratory disease planning air travel : British Thoracic Society recommendations. Thorax. 2011 ; 66 : Suppl 1 : i1-30.

P.834 掲載の参考文献

1) Travis WD, et al. World Health Organization Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon : World Health Organization ; 2014.

2) 日本呼吸器外科学会, 呼吸器外科専門医合同委員会 (編). 呼吸器外科テキスト-外科専門医・呼吸器外科専門医をめざす人のために-. 東京 : 南江堂 ; 2016.

3) 中野孝司. 胸膜全書胸膜疾患のグローバルスタンダード. 東京 : 医薬ジャーナル社 ; 2013.

4) 工藤翔二, 他 (編). 呼吸器専門医テキスト. 東京 : 南江堂 ; 2007.

5) 深山正久, 他 (編). 縦隔腫瘍・胸膜腫瘍腫瘍病理鑑別診断アトラス. 東京 : 文光堂 ; 2014.

P.837 掲載の参考文献

1) Drake RL, et al. Gray's Anatomy for Students, 2nd ed. Tokyo : Elsevier Japan ; 2011.

2) 日本呼吸器外科学会, 呼吸器外科専門医合同委員会 (編). 呼吸器外科テキスト-外科専門医・呼吸器外科専門医をめざす人のために-. 東京 : 南江堂 ; 2016.

P.840 掲載の参考文献

1) Locicero J, et al. General Thoracic Surgery 6th edn. Philadelphia : Lippincott Williams & Wilkins ; 2004.

2) Park SY, et al. Value of 18F-FDG PET/CT for Predicting the World Health Organization Malignant Grade of Thymic Epithelial Tumors : Focused in Volume-Dependent Parameters. Clin Nucl Med. 2016 ; 41 : 15-20.

3) Venuta F, et al. Thymoma and thymic carcinoma. Gen Thorac Cardiovasc Surg. 2012 ; 60 : 1-12.

P.843 掲載の参考文献

1) 日本肺癌学会. EBMの手法による肺癌診療ガイドライン 2016年版悪性胸膜中皮腫・胸腺腫瘍含む. 2016. pp. 297-323.

2) Hamaji M. The role of adjuvant chemotherapy following resection of early stage thymoma. Ann Cardiothorac Surg. 2016 ; 5 : 45-50.

3) Hamaji M, et al. A meta-analysis of debulking surgery versus surgical biopsy for unresectable thymoma. Eur J Cardiothorac Surg. 2015 ; 47 : 602-7.

4) Hamaji M, et al. A Meta-Analysis of Postoperative Radiotherapy for Thymic Carcinoma. Ann Thorac Surg. 2017 ; 103 : 1668-75.

5) Hamaji M, et al. A meta-analysis of induction therapy for advanced thymic epithelial tumors. Ann Thorac Surg. 2015 ; 99 : 1848-56.

6) CCN clinical practice guidelines in Oncology. Thymomas and Thymic Carcinomas Version 3. 2016 available at, NCCN, https://www.nccn.org/professionals/physician_gls/PDF/thymic.pdf.

7) Hamaji M, et al. The role of surgical management in recurrent thymic tumors. Ann Thorac Surg. 2012 ; 94 : 247-54.

8) Filosso PL, et al. Thymoma and the increased risk of developing extrathymic malignancies : a multicentre study. Eur J Cardiothorac Surg. 2013 ; 44 : 219-24.

9) Weksler B, et al. Resection of thymoma should include nodal sampling. J Thorac Cardiovasc Surg. 2015 ; 149 : 737-42.

10) Gu Z, et al. Lymph node metastases in thymic malignancies : a Chinese Alliance for Research in Thymomas retrospective database analysis. Interact Cardiovasc Thorac Surg. 2017 ; 25 : 455-61.

P.846 掲載の参考文献

1) Tapper D, et al. Teratomas in infancy and childhood. A 54-year experience at the Children's Hospital Medical Center. Ann Surg. 1983 ; 198 : 398-410.

2) Harms D, et al. Immature teratomas of childhood. Report of 21 cases. Pathol Res Pract. 1985 ; 179 : 388-400.

3) Knapp RH, et al. Malignant germ cell tumors of the mediastinum. J Thorac Cardiovasc Surg. 1985 ; 89 : 82-9.

4) Takeda S, et al. Primary germ cell tumors in the mediastinum : a 50-year experience at a single Japanese institution. Cancer. 2003 ; 97 : 367-76.

5) Dulmet EM, et al. Germ cell tumors of the mediastinum. A 30-year experience. Cancer. 1993 ; 72 : 1894-901.

6) Bokemeyer C, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum : results from an international analysis. J Clin Oncol. 2002 ; 20 : 1864-73.

7) Samuels ML, et al. Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy. JAMA. 1976 ; 235 : 1117-20.

8) Schultz SM, et al. Management of postchemotherapy residual mass in patients with advanced seminoma : Indiana University experience. J Clin Oncol. 1989 ; 7 : 1497-503.

9) Puc HS, et al. Management of residual mass in advanced seminoma : results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol. 1996 ; 14 : 454-60.

10) International Germ Cell Consensus Classification : a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997 ; 15 : 594-603.

11) Ranganath P, et al. Perioperative Morbidity and Mortality Associated With Bleomycin in Primary Mediastinal Nonseminomatous Germ Cell Tumor. J Clin Oncol. 2016 ; 34 : 4445-6.

12) Hartmann JT, et al. Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst. 2000 ; 92 : 54-61.

P.848 掲載の参考文献

1) Hattori H. Ciliated cyst of probable mullerian origin arising in the posterior mediastinum. Virchows Arch. 2005 ; 446 : 82-4.

P.851 掲載の参考文献

1) 船津武志, 他. 気管気管支軟化症. 気管支学. 1982 ; 4 : 123-35.

2) 池田貞雄, 他. 気管・気管支軟化症の病態と外科治療. 日胸疾会誌. 1992 ; 30 : 1028-35.

3) Pathak V, et al. Tracheobronchial tuberculosis. J Thorac Dis. 2016 ; 8 : 3818-25.

4) 荒井他嘉司. 気管支結核の新しい気管支鏡所見分類の有用性について. 気管支学. 2001 ; 23 : 352-60.

5) Li Z, et al. Surgical approaches of endobronchial neoplasms. J Thorac Dis. 2013 ; 5 : S378-82.

P.854 掲載の参考文献

1) McCool FD, et al. Dysfunction of the Diaphragm. N Eng J Med. 2012 ; 366 : 932-42.

2) Chandrasekharan PK, et al. Congenital Diaphragmatic hernia -a review. Matern Health Neonatol Perinatol. 2017 ; 3 : 6.

3) 正岡昭 (監), 藤井義敬 (編). 呼吸器外科学. 東京 : 南山堂 ; 2009.

4) Shinohara S, et al. Phrenic Nurve Reconstruction and Bilateral Diaphragm Plication After Lobectomy. Ann Thorac Surg. 2017 ; 104 : e9-11.

P.857 掲載の参考文献

1) Jaroszewski D, et al. Current Management of Pectus Excavatum : A Review and Update of Therapy and Treatment Recommendations. J Am Board Fam Med. 2010 ; 23 : 230-9.

2) Nuss D, et al. A 10-Year Review of a Minimally Invasive Technique for the Correction of Pectus Excavatum. J Pediatr Surg. 1998 ; 33 : 545-52.

3) Abdullah F, et al. Pectus Excavatum : More Than a Matter of Aesthetics. Pediatr Ann. 2016 ; 45 : e403-6.

4) Mao YZ, et al. Comparison of the Nuss versus Ravitch procedure for prectus excavatum repair : an updated meta-analysis. J Pediatr Surg. 2017 ; 52 : 1545-52.

P.860 掲載の参考文献

1) Widhe B, et al. Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall : a population-based Scandinavian Sarcoma Group study of 106 patients. J Thorac Cardiovasc Surg. 2009 ; 137 : 610-4.

2) Ueda T, et al. Pyothorax-associated lymphoma : imaging findings. AJR Am J Roentgenol. 2010 ; 194 : 76-84.

P.863 掲載の参考文献

1) 畠中陸郎, 他. 呼吸器外科手術書改訂5版. 東京 : 金芳堂 ; 2007.

2) 日本外傷学会, 日本救急医学会. 改訂第4版外傷初期診療ガイドライン. 東京 : へるす出版 ; 2012.

P.867 掲載の参考文献

1) 日本外傷学会臓器損傷分類委員会. 胸郭損傷分類 2008. 日外傷会誌. 2008 ; 22 : 268.

P.869 掲載の参考文献

1) Gaillard M, et al. Mortality prognostic factors in chest injury. J Trauma. 1990 ; 30 : 93-6.

2) Shorr RM, et al. Blunt thoracic trauma. Analysis of 515 patients. Ann Surg. 1987 ; 206 : 200-5.

3) Arajarvi E, et al. Chest injuries sustained in severe traffic accidents by seatbelt wearers. J Trauma. 1989 ; 29 : 37-41.

4) Knobloch K, et al. Sternal fractures occur most often in old cars to seat-belted drivers without any airbag often with concomitant spinal injuries : clinical findings and technical collision variables among 42,055 crash victims. Ann Thorac Surg. 2006 ; 82 : 444-50.

5) Tanaka H, et al. Surgical stabilization of internal pneumatic stabilization? A prospective randomized study of management of severe flail chest patients. J Trauma. 2002 ; 52 : 727-32.

6) 日本外傷学会外傷初期診療ガイドライン改訂第4版編集委員会 (編). 外傷初期診療ガイドラインJATEC 第4版. 東京 : へるす出版 ; 2012.

P.871 掲載の参考文献

1) Richardson JD, et al. Selective management of flail chest and pulmonary contusion. Ann Surg. 1982 ; 196 : 481-7.

2) Deunk J, et al. The clinical outcome of occult pulmonary contusion on multidetector-row computed tomography in blunt trauma patients. J Trauma. 2010 ; 68 : 387-94.

3) Livingston DH, et al. Trauma to the chest wall and lung. In : Trauma. 5th ed. New York : McGraw-Hill ; 2004.

4) Pryor JP, et al. Thoracic Surgery. In : The Trauma Manual. 2nd ed. Philadelphia : Lippincott Williams and Wilkins ; 2002. p.203-23.

5) 日本外傷学会外傷初期診療ガイドライン改訂第4版編集委員会. 外傷初期診療ガイドラインJATEC 第4版. 東京 : へるす出版 ; 2012.

P.874 掲載の参考文献

1) Fair KA, et al. Traumatic diaphragmatic injury in the American College of Surgeons National Trauma Data Bank : a new examination of a rare diagnosis. Am J Surg. 2015 ; 209 : 864-8 ; discussion 8-9.

2) Shah R, et al. Traumatic rupture of diaphragm. Ann Thorac Surg. 1995 ; 60 : 1444-9.

3) 日本外傷学会臓器損傷分類委員会. 日本外傷学会臓器損傷分類 2008. 日外傷会誌. 2008 ; 22.

4) 茂木晃. VII. 胸部外傷・その他. 6. 横隔膜損傷. 日本呼吸器外科学会, 呼吸器外科専門医合同委員会 (編). 呼吸器外科テキスト-外科専門医・呼吸器外科専門医をめざす人のために-. 東京 : 南江堂 ; 2016. pp. 302-5.

P.877 掲載の参考文献

1) 森脇義弘, 他. 鈍的外傷による気管損傷のCT像の特徴気管周囲低吸収域と連続する気腫像. 日救急医会誌. 2003 ; 14 : 54-61.

2) 前原潤一, 他. 転落による鈍的喉頭気管支完全断裂の1救命例. 日救急医会誌. 2016 ; 27 : 87-92.

3) Besson A, et al. Trauma of the trachea and major bronchi. Chest Trauma. 1982 ; 2 : 9-80.

4) Wain JC. Postintubation tracheal stenosis. Chest Surg Clin N Am. 2003 ; 13 : 231-46.

5) 久貝忠男. 気管腕頭動脈瘻 4例の検討. 日血外会誌. 2004 ; 13 : 691-4.

P.879 掲載の参考文献

1) 日本外傷学会臓器損傷分類委員会. 胸部損傷分類 2008. 日本外傷学会外傷用語集 (改訂版 2008). 東京 ; 春恒社 : 2008. p53.

2) 新谷知久, 他. 経皮的心肺補助 (PCPS) 作動下に修復術を施行した右主気管支完全断裂の1例. 日救急医会誌. 2000 ; 11 : 705-9.

3) Liu C, et al. Extracorporeal membrane oxygenation as a support for emergency bronchial reconstruction in a traumatic patient with severe hypoxaemia. Interact Cardiovasc Thorac Surg. 2014 ; 19 : 699-701.

4) Brichet A, et al. Multidiscip] inary approach to management of postintubation tracheal stenoses. Eur Respir J. 1999 ; 13 : 888-93.

5) 井上考司, 他. フルチカゾン吸入が有効であった気管形成術後吻合部肉芽狭窄の1例. 気管支学. 2014 ; 36 : 143-6.

P.880 掲載の参考文献

1) 成松英智, 他. 挿管困難をきたした不完全型外傷性気管断裂の1例. 日本臨床麻酔学会誌. 1993 ; 13 : 581-4.

2) 前原潤一, 他. 転落による鈍的喉頭気管支完全断裂の1救命例. 日救急医会誌. 2016 ; 27 : 87-92.

3) Prokakis C, et al. Airway trauma : a review on epidemiology, mechanisms of injury, diagnosis and treatment. J Cardiothorac Surg. 2014 ; 9 : 117.

4) 高坂知節. 救急医療について緊急気管切開. 日気食会報. 1989 ; 40 : 444-5.

P.883 掲載の参考文献

1) Shirani KZ, et al. The influence of inhalation injury and pneumonia on burn mortality. Ann Surg. 1987 ; 205 : 82-7.

2) emedicine.medscape.com/article/771194-overview (Accessed on November 23, 2015).

3) Endorf FW, et al. Inhalation injury, pulmonary perturbations, and fluid resuscitation. J Burn Care Res. 2007 ; 28 : 80-3.

4) Woodson LC, et al. Diagnosis and treatment of inhalation injury. In Herndon D, ed. Total Burn Care. 4th ed. Philadelphia : WB Saunders ; 2012. pp. 232.

5) Cioffi WG Jr, et al. Prophylactic use of high-frequency percussive ventilation in patients with inhalation injury. Ann Surg. 1991 ; 213 : 575-80. discussion 580-2.

6) Acute Respiratory Distress Syndrome Network, Brower RG, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000 ; 342 : 1301-8.

7) Holt J, et al. Use of inhaled heparin/N-acetylcystine in inhalation injury : does it help? J Burn Care Res. 2008 ; 29 : 192-5.

8) Haburchak DR, et al. Use of systemic antibiotics in the burned patient. Surg Clin North Am. 1978 ; 58 : 1119-32.

9) Cha SI, et al. Isolated smoke inhalation injuries : acute respiratory dysfunction, clinical outcomes, and short-term evolution of pulmonary functions with the effects of steroids. Burns. 2007 ; 33 : 200-8.

P.885 掲載の参考文献

1) Mu L, et al. Inhalation of foreign bodies in Chinese children : a review of 400 cases. Laryngoscope. 1991 ; 101 : 657-60.

2) Boyd M, et al. Tracheobronchial foreign body aspiration in adults. South Med J. 2009 ; 102 : 171-4.

3) Saliba J, et al. Asthma : the great imitator in foreign body aspiration? J Otolaryngol Head Neck Surg. 2012 ; 41 : 200-6.

4) Limper AH, et al. Tracheobronchial foreign bodies in adults. Ann Intern Med. 1990 ; 112 : 604-9.

5) Duan L, et al. Surgical treatment of late-diagnosed bronchial foreign body aspiration : a report of 23 cases. Clin Respir J. 2014 ; 8 : 269-73.

書評

書評を投稿する

最近チェックした商品履歴

Loading...